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Abstract 
Familial hypertrophic cardiomyopathy and other cardiovascular diseases result 
from mutations of any of the contractile proteins. Mutations within the actin binding 
regulatory complex of proteins, including tropomyosin (Tm) and the three subunits of the 
troponin (Tn) complex (TnI, TnC, and TnT), change the operation of the Ca2+ dependent 
3-way switch that controls movement. The Δ14-TnT mutation, which is missing the last 
14 residues of its C-terminus, is particularly important as it leads to hypertrophic 
cardiomyopathy and early sudden death. Our laboratory found that incorporation of 
Δ14-TnT into the regulatory complex stabilizes the open (M) state and removes the 
blocked (B) state from the actin state distribution. This suggests the last fourteen 
residues of the C-terminus of TnT are essential in maintaining the open state and the 
blocked state of the thin filament. This function had not previously been attributed to 
TnT. 
Our lab aims to identify the key residues of TnT that are responsible for normal 
state distribution. This information will allow us to identify possible mechanisms of action 
of TnT and would facilitate the design of treatments of myopathies. We prepared 
truncation mutants of TnT that included Δ4, Δ6, Δ8, Δ10 and Δ14. We utilized two 
stopped flow kinetic assays and an ATPase assay to determine the effect of these 
deletions on the state distributions. Each assay supported the idea that successive 
deletions resulted in further diminished function. We conclude that all of the fourteen 
residues of the TnT C-terminus contribute to a similar extent to the function. 
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Preface 
Deletion of the 14 C-terminal amino acid residues from cardiac troponin T (a 
regulatory protein of contraction) is known to lead to a serious form of cardiac disease 
known as familial hypertrophic cardiomyopathy. While investigating how changes in the 
structure of this part of troponin T cause heart disease, our laboratory discovered 
unique regulatory functions of this region of troponin. The C-terminal region of troponin 
T is essential for fully inactivating muscle contraction at low calcium conditions (relaxing 
conditions). That same region also prevents full activation at high calcium conditions 
(activating conditions).  
Several cardiac and skeletal disorders result from changes in regulation of 
contraction. Current attempts at treatment are targeted to the known functions of 
troponin that operate through calcium binding to troponin C. The identification of a new 
regulatory region means that new approaches to normalizing regulation are possible. 
Normalizing regulation requires knowing how that C-terminal region of troponin T 
functions. The primary goal of this work is to determine which amino acid residues in 
this region of troponin T are required for these newly identified effects. Future work will 
then be directed to finding the binding partners of these identified residues and in 
defining the pathway of regulation. It then may be possible to modulate the effect of the 
C-terminal region to effect a therapeutic change in contraction.  
In order to determine which of troponin T residues are required for these newly 
identified effects, we had to use assays that would report the effect of deletions of the 
C-terminal region of troponin T on the process of switching from the inactive to the 
active state. This is difficult because the regulatory switch has three positions. There are 
 two inactive states (blocked, B and closed, C) and one active state (open, M). Two 
equilibrium constants control the distribution among these states and different methods 
are required to measure each equilibrium constant and the rates of transition from one 
state to another. 
ATPase assays are the best means to estimate the fraction of actin-tropomyosin-
troponin (the regulatory complex) in the open, M, state as only the M state has 
appreciable ATPase activity. Because the blocked, B, and closed, C, states are both 
inactive it is necessary to distinguish between them by a change in structure. Our 
laboratory discovered that there is a fluorescence change in acrylodan probes on 
tropomyosin when moving between the B and C states. Methods based on this 
fluorescence change gives both the equilibrium constant between the blocked and 
closed states and the rate constants for the transition.  
A method developed by other investigators in the USA and England gives an 
independent measure of the B state. Although it has limitations, we employ this method 
also. The biggest limitation of the method is that it has not been demonstrated to relate 
to function. We therefore intend to correlate the results of the different methods to 
determine their predictive value. 
In looking at the effects of the C-terminal region of troponin T on the distribution 
of actin-tropomyosin-troponin regulatory states it is necessary to have some established 
controls for comparison of the deletion mutants. Troponin T lacking its 14 C-terminal 
residues (Δ14 TnT) is used in all assays as a measure of maximum possible activation. 
We use A8V troponin C along with Δ14 TnT to define the fully activated state where 
virtually 100% of the actin-tropomyosin-troponin is in the open M state. Wild type 
 troponin, at low calcium, is used to define the blocked B state. We use R146G TnI to 
define the other inactive state, the closed C state. As such, we are able to examine 
each of the states independently.  
In using the A8V TnC and R146G TnI mutants, we have added to the knowledge 
base of these cardiac disease causing mutations also. The results pertaining to these 
mutants will be summarized separately.  
The thesis is divided into six chapters. Chapter 1 gives the essential background 
necessary to understand our primary question. That section reviews cardiomyopathies, 
muscle contraction, models for regulation, necessary structural information and how 
structural changes affect cardiovascular function. Chapter 2 describes the major 
methods used in this study. Chapter 3 gives the results and discussion of deletion 
mutants of Troponin T, our major interest. Chapters 4 and 5 contain the Results and 
Discussion of R146G troponin I and A8V troponin C, respectively. Chapter 6 is a 
summary of all of the work. Finally, appendices are included that give details for some 
of the methods used in this study.
 Chapter 1: Background 
Cardiomyopathy 
Hypertrophic Cardiomyopathy is a leading cause of sudden death and is caused by 
mutations in any of the contractile or structural proteins of cardiac or skeletal muscle.  
An article published in 1994 1 linked mutations in the actin regulatory components 
tropomyosin and troponin T to familial hypertrophic cardiomyopathy (HCM). Since then, 
over thirty mutations in troponin T have been linked to HCM. Familial Cardiomyopathies 
are among the leading causes of sudden cardiac death 2. The world health organization 
classified cardiomyopathies into four main groups including hypertrophic 
cardiomyopathy (HCM), dilated cardiomyopathy (DCM), restrictive cardiomyopathy 
(RCM), and arrhythmogenic right ventricular cardiomyopathy (ARVC). HCM is one of 
the most common genetic disorders affecting one in every 500 people or approximately 
600,000 people in the United States 2.  
The hearts of those afflicted with myopathies undergo morphological changes as an 
initially beneficial compensatory mechanism to maintain normal blood flow (Figure 1) 3. 
It is this same compensatory mechanism that is believed to ultimately cause heart 
failure. The myocardium of the left ventricle of those afflicted is thickened and become 
less flexible over time as a result of the morphological changes often associated with 
HCM. This diminished flexibility results in reduced capacity of the left ventricle and 
reduced outflow of blood from the heart. Those afflicted may be initially asymptomatic 
but develop symptoms proportional to the enlargement of the myocardium. One of the 
first symptoms of this disease is sudden cardiac death. Other symptoms include 
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shortness of breath, chest pain, rapid or irregular heartbeat, dizziness upon standing, 
lightheadedness, muscular weakness, blurred vision, and fainting 3. 
 
 
Figure 1: Compensatory morphological differences can be observed in the heart of 
patient afflicted with HCM. Left) Normal Heart. Right) Heart of Person Afflicted with 
HCM4 
 
Hypertrophic Cardiomyopathy is most commonly diagnosed using noninvasive 
cardiac imaging including echocardiography and cardiac MRI. The disease can also be 
diagnosed through family history and genetic testing for gene markers that encode 
components of the sarcomere. No treatments are available to slow or reverse disease 
development 3. Pharmacological measures to reduce symptoms include treatment with 
beta blockers or L-type calcium channel blockers. These treatments are used to slow 
heart rate and allow time for more diastolic filling. If diastolic dysfunction cannot be 
managed, invasive septal reduction is often necessary to alleviate symptoms. 
A preferable way to manage cardiomyopathy is to restore normal function to the 
affected proteins, in our case the subunits of the troponin complex. In order to 
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accomplish this, it is necessary to understand how the individual mutations alter 
function. 
There are several hypotheses linking structural changes to the development of 
cardiac dysfunction including inefficient energy utilization, problems with calcium 
homeostasis and other such changes. A difficulty in finding the root cause of 
dysfunction is that cardiomyopathy may develop from mutations in troponin that 
increase calcium sensitivity as well as from those that have the opposite effect. Our lab 
investigated a series of mutants to try to uncover a pattern. In the case of several 
mutants examined involving TnT (Gafurov 2004), TnI (Mathur 2008, 2009) and TnC 
(Baxley 2014) the primary effect of the mutation was on the rate of switching and the 
equilibrium among the blocked, closed and open states of actin-tropomyosin. In order to 
understand the significance of those observations it is necessary to understand how the 
tropomyosin-troponin switch operates to control the degree of acceleration of ATP 
hydrolysis by myosin that is stimulated by actin. This actomyosin ATPase activity is the 
driving force for movement.  
Myosin is an ATPase that hydrolyzes ATP at a slow rate as a result of the rate 
limiting release of products. The binding of myosin to actin accelerates the rate of ATP 
hydrolysis by several hundred-fold. The ability of actin to accelerate the ATPase activity 
is controlled by different mechanisms in different muscle types. Regulation by skeletal 
and cardiac muscle occur through the regulatory proteins tropomyosin and troponin. 
The ATPase activity and its regulation are discussed below. 
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Myosin ATPase Activity 
Myosin hydrolyzes ATP at a relatively slow rate through the reaction scheme 
steps 1’, 3’ and 5’ shown in Figure 2. Hydrolysis occurs significantly more rapidly when 
crossbridges form between actin and myosin to form actomyosin in the presence of 
magnesium 5 following the reaction scheme [Figure 2] steps 1, 2, 3’,4, 5, 6, 7, and 8 
 
 
Figure 2: Myosin ATPase Crossbridge Cycle. (-) indicates a weakly bound collision 
complex. (*) indicates interaction. (“) indicates a strongly bound state. 
 
In the first step of the reaction scheme, myosin or actomyosin forms a collision 
complex with ATP and subsequently isomerizes to a more stable complex with ATP 
(steps 1’ or 1) at similar rates of about 106 M-1 s-1. Upon binding of ATP to actomyosin, 
myosin-ATP rapidly dissociates from actin (step 2 of Figure 2) as ATP decreases the 
affinity of myosin for actin. It was observed that ATPase rates were higher when binding 
of HMM (heavy meromyosin fragment of myosin) to actin was low6. Although cleavage 
of ATP by actomyosin can be observed at low ionic strengths, it is significantly slower 
than cleavage by myosin alone and has a Keq of less than one 7. At physiological ionic 
strength, cleavage of ATP phosphoanhydride by myosin occurs almost entirely after 
dissociation from actin.  
After hydrolysis of ATP, myosin temporarily holds onto the ADP and Pi products. 
Pi is not appreciably released by myosin unbound to actin (step 5’ of Figure 2). 
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Myosin*ADP*Pi more favorably forms a collision complex with actin (step 4 of Figure 2) 
which isomerizes to a more closely associated complex (step 5 of Figure 2). Eisenberg 8 
proposed a model where there is a slow ATPase rate limiting isomerization of myosin 
before formation of the myosin-ATP collision complex. Favorable formation of the 
closely associated complex is thought to be dependent on calcium stimulation of the 
troponin complex 9, 10 although the mechanism by which calcium controls this transition 
is debated (See 11) 
 Following formation of the closely associated complex, fibers studies 12,13 
suggest that myosin undergoes the mechanical force producing step (step 6 of Figure 2) 
responsible for pulling itself along actin then releases its bound Pi (step 7 of Figure 2). 
Although fiber studies support that steps 6-7 in Figure 2 occur in sequence 12–14, it has 
also been suggested that steps 6-7 and even steps 5-7 occur simultaneously 15, 16,17. 
Regardless, it is known that either step 5, 6 or 7 or a combination of them are 
responsible for the mechanical force producing step based on the change in free energy 
between those states 18,19. After step 7 of Figure 2, actomyosin undergoes an 
isomerization followed by a rapid release of ADP (step 8 of Figure 2) 20,21. It has also 
been suggested that the isomerization could be the ATPase rate limiting step 22. 
Different models developed to explain how calcium exhibits it’s regulation of the myosin 
ATPase are described below. 
 
Regulation of Myosin ATPase Activity 
Regulation of cardiac and skeletal muscle contraction is dictated by the 
orientation of tropomyosin on actin. Calcium binding by troponin effects the tropomyosin 
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orientation. Models hypothesized to explain how calcium exerts its regulation include a 
classical steric blocking model and models proposed by Hill 23 and Geeves 24 (Figure 3).  
The classical steric blocking model describes regulation of the myosin ATPase 
with only a blocked and an open state of actin. The blocked state is stabilized by the 
absence of calcium whereas the open state is stabilized by the presence of calcium. 
This classical model is not supported by the evidence of a third regulatory state of actin 
24. 
The model proposed by Hill consists of three states of actin in which myosin-ATP 
can bind to any of the states: 10, 12, or 2n. In the Hill model, the 10 state is stabilized by 
the absence of calcium, the 12 state is stabilized by the presence of calcium but does 
not have maximal ATPase activity, and the 2n state is stabilized by rigor S1 (S1 in the 
absence of ATP) binding and exhibits maximal ATPase activity regardless of calcium 
concentration. The model proposed by Geeves differs from the Hill model in four ways. 
The Geeves model states: 1) Myosin cannot bind to the blocked state 2) Calcium must 
be present for rigor myosin to bind and stabilize the open state 3) The states are 
sequential in that you have to pass through the closed state when switching between 
the blocked and open states.  
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Figure 3: Schematic of regulation as described by each model25 A) Classical steric 
blocking Model B) Hill Model C) Geeves Model 
 
The Hill and Geeves model fundamentally differ in that the Hill model views 
tropomyosin to function in modulating actin stimulatory function whereas the Geeves 
model views tropomyosin to function in blocking myosin binding. Although identification 
of the mechanism by which the position of tropomyosin dictates the state of actin is of 
importance, the experimental evidence herein is concerned with the mechanism by 
which troponin causes tropomyosin movement. Either step 4 or step 5 of the reaction 
scheme (Figure 2) is regulated by calcium via troponin and is the step where troponin is 
thought to induce tropomyosin movement. Understanding the structure of the regulatory 
complex and how subunits interact is important to understanding how mutations effect 
interactions. The structure of the regulatory complex and some of the known 
interactions of the troponin subunits are described below. 
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The Myosin ATPase Regulatory Complex 
Regulated thin filaments are composed of actin, tropomyosin and troponin. Actin, 
tropomyosin and troponin interact with a stoichiometric ratio of seven actin monomers 
for every one tropomyosin and troponin 26.Polymeric actin (F-actin) is composed of 42 
kDa actin monomers (G-actin). Every 28 monomers extend 770 Angstroms in 13 left 
handed turns with each actin monomer rotated 167 degrees 27 to form a two stranded 
long-pitch helix. Each actin monomer is composed of four subdomains (Figure 4). 
Subdomains 3 and 4 are axial and interact with subdomains 3 and 4 of the adjacent 
strand. Subdomains 1 and 2 are peripheral and exposed to solvent or myosin binding. 
An effect of myosin on actins atomic structure has been detected 28. 
 
Figure 4: Space filling models from electron micrographs a) actin showing subdomains 
1-4. b) actin with tropomyosin position overlayed. c) tropomyosin coiled coil 29 
 
Tropomyosin (Tm) is a highly negatively charged dimer of two 35 kDa 
polypeptide chains. Tropomyosin can be a homodimer or heterodimer of alpha and beta 
chains with alpha chain homodimers dominating for cardiac muscle in large mammals. 
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Alanine residues intrinsically force tropomyosin into a coiled-coiled coil that conforms to 
actins long pitch helices (Figure 4) 30.Each tropomyosin dimer has fourteen acidic amino 
acid dense regions 31. Tropomyosin is electrostatically stabilized on actin by a positively 
charged region of the actin long pitch helix that spans seven actin monomers 32. The 
sevenfold repeat of tropomyosin ensures that each actin that tropomyosin spans has a 
similar environment 33. Adjacent tropomyosin overlap to form a continuous strand along 
the actin long-pitch helix. The overlap region is highly flexible and contributes 
significantly to the affinity of tropomyosin for actin 34.  
Binding of myosin to an actin monomer was previously thought to promote further 
cooperative binding of myosin to nearby actin monomers interacting with the same 
tropomyosin monomer. It is now believed myosin binding to actin promotes further 
myosin binding to any nearby actin monomers. Myosin binds to actin in the presence of 
tropomyosin with more than 4 fold greater affinity than to bare actin 35. Myosin increases 
the affinity of tropomyosin for actin by 10,000 fold or more. This suggests myosin and 
tropomyosin induce conformational change of actin 36. It is suggested that the actin 
conformational change allows tropomyosin to shift toward the inner domain of actin 
regardless of calcium concentration.  
Evidence of tropomyosin movement in response to calcium comes from x-ray 
data 37 and electron microscope data 38. The x-ray data showed a transition from a 
structure with strong twofold symmetry to a structure with strong fourfold symmetry 
upon addition of calcium. This change in symmetry was attributed to a calcium induced 
azimuthal shift of tropomyosin along actin. This azimuthal movement was confirmed by 
3D reconstructions of electron microscopy data 39 (Figure 5). A third regulatory state 
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was suggested to be present in which tropomyosin is pushed further into the actin 
groove. Electron microscope data showed that upon addition of calcium, tropomyosin 
shifted 25 degrees from its low calcium position 40. Furthermore, upon addition of 
myosin, tropomyosin shifted another 10 degrees.  
 
 
Figure 5: Ribbon Diagram computationally generated from EM data showing actin with 
tropomyosin in different positions depending on conditions. Red, EGTA; Yellow, 
Calcium; Green, Rigor (No ATP) 39 
 
The troponin complex is composed of troponin C (TnC), troponin I (TnI), and 
troponin T (TnT) which cooperate to modulate actin-myosin and actin-tropomyosin 
interaction (Figure 6). Troponin I functions in binding to TnC and TnT and holding them 
onto actin. The human cardiac isoform of TnI is made up of 210 amino acids and 
consists of an acidic N-terminal domain (2-32), a structural IT-arm (residues 32-136), 
inhibitory domain (or inhibitory region) (residues 137-148), regulatory domain (or 
regulatory region) (149-160) and a C-terminal domain (163-210) (Figure 7) 41. The N-
terminal methionine residue is removed during synthesis and the adjacent alanine is 
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acetylated 41,42. For the extent of this document, the N-terminal methionine is 
considered amino acid one and all sources have been normalized to include this in the 
count. The acidic N-terminal domain (residues 2-32) is present only in the cardiac 
isoform. Serine residues 23 and 24 of this region have been shown to be readily 
phosphorylated by PKA resulting in increased calcium sensitivity, increased crossbridge 
cycling rate, and increased shortening velocity 43–46. When dephosphorylated, the N-
terminal residues 19-33 interact with the N-lobe of TnC 47. Upon phosphorylation, 
residues 19-33 of the N-terminal region of TnI form an alpha helix and no longer 
interacts with TnC 43. The phosphorylated N-terminal of TnI is believed to interact with 
the basic inhibitory domain of TnI which would influence calcium regulation. Serine 43 
and 45 and threonine 144 are targets of phosphorylation by PKC.  
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Figure 6: Diagram illustrating the position of tropomyosin and the subunits of troponin 
along actin 48 
 
Residues 44-80 and 91-136 within the IT arm of TnI makeup the H1 and H2 
alpha helices respectively. An amphiphilic portion (residues 44-66) of the H1 alpha-helix 
interacts with the C-terminal structural domain of TnC 49. Residues 67-80 of the H1 
alpha helix interact with the H2 alpha helix of TnT 49. The H2 alpha helix of TnI interacts 
with the H2 alpha helix of TnT (residues 227-272).The calcium dependent interactions 
of the inhibitory domain (residues 138-149 50 or 130-149 51) of TnI function in moving 
tropomyosin between positions that promote or inhibit actomyosin formation. In the 
absence of calcium, residues 139-149 of TnI interact with actin and hold tropomyosin in 
a position that limits myosin interaction with actin 52. The affinity of TnI for TnC is 
enhanced by the presence of calcium 53. Brown 54 and Takeda 55 showed little 
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secondary structure of residues 138-148 in the absence of calcium. In the presence of 
calcium, residues 136-141 on TnI form an alpha helix that has lower affinity for actin and 
instead interacts with the N-terminal of TnC 51. Kobayashi 50 showed absence of 
secondary structure between residues 142-149 of TnI in the presence of calcium.  
Residues 151-160 of TnI make up the H3 alpha helix (or regulatory domain or 
switch region) of TnI 55. At high calcium concentration, the H3 alpha helix interacts with 
a hydrophobic cleft that opens on the N-lobe of TnC 56. This interaction corresponds 
with the dissociation of the TnI inhibitory domain from actin and movement of the mobile 
domain that enhances myosin-actin interaction 49,56.  
 
 
Figure 7: Schematic of Troponin I showing locations of interactions (A) and important 
regions (B) 57. The inhibitory domain (ID), regulatory domain (RD) and mobile domain 
are calcium sensitive. 
 
Troponin T is known as the tropomyosin binding subunit and functions in holding 
actin, tropomyosin, troponin I, and troponin C together. There is now evidence for its 
participation in regulation of contraction 58. The most common human cardiac isoform of 
TnT is made up of 288 amino acids. The N-terminal methionine residue is removed 
during synthesis and the adjacent serine is acetylated 59. As mentioned for TnI above, 
some sources do not count the N-terminal methionine when identifying regions of TnT. 
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For the extent of this document, the N-terminal methionine is considered amino acid 
one and all sources have been normalized to include this residue in the count. The four 
cardiac isoforms cTnT1-cTnT4 are produced by alternative splicing at exons 4 and 5 
60,61 and are thought to alter thin filament calcium response. TnT contains up to four 
target sites for phosphorylation by PKC. TnT contains an extended N-terminal region 
(TnT1,residues 2-68) that extends about half the length of tropomyosin 58 and a globular 
region (TnT2, residues 69-288) (Figure 8). The globular region consists of a conserved 
region (residues 69-200) and C-terminal region (residues 201-288). The conserved and 
C-terminal regions are connected by a flexible linker made up of residues 183-200. 
Similar to TnI, the cardiac isoform of TnT has an additional highly polar and negatively 
charged 32 amino acid region on its N-terminal that is absent in skeletal isoforms. Early 
experiments on N-terminal fragments of TnT showed that the region does not interact 
with other troponin subunits, actin, or tropomyosin 62. However, experiments 
incorporating TnT N-terminal mutations revealed that the region has an effect on 
conformation, subunit interaction, calcium response, and force development 57. The T1 
region of TnT (residues 98-136) interacts with the tropomyosin overlap region in a 
calcium independent manner 57. Evidence suggests that an alpha-helical region of TnT 
interacts with tropomyosin to form a triple stranded coiled-coil with one-third of the 
length of the tropomyosin C-terminal 63. 
Residues 204-220 of the C-terminal domain of TnT make up the H1 alpha helix 
and residues 227-272 make up the H2 alpha helix 55. The H2 alpha helix of TnT forms a 
coiled coil with the H2 alpha helix of TnI 64. TnT residues 257-271 of the H2 alpha helix 
also interact with the calcium binding loops within the TnC C-terminal domain 55. A 
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second TnT-tropomyosin interaction is present between the C-terminal of TnT and a 
region near cys190 of tropomyosin 65. The interaction is enhanced in the absence of 
calcium 66. The T2 region consists of either residues 197-239 67 or the last sixteen 
residues of the C-terminal 272-288 57. The last sixteen residues of the C-terminal of TnT 
have not been resolved in crystal structures of troponin suggesting structural flexibility 
or interaction with another thin filament subunit 55.  
 
Figure 8: Schematic of Troponin T showing locations of interactions (A) and important 
regions (B) 57 
 
Troponin C is known as the calcium sensing subunit. The human cardiac isoform 
of TnC is composed of 161 amino acids 68. Residues 1-13 of TnC form a short alpha 
helix. Residues 92-161 of TnC form a globular region. Residues 14-87 make up two 
pairs of calcium binding EF hand domains. A pair of EF hand domains is located in both 
the N-terminal (residues 1-87) and C-terminal (residues 92-161) (Figure 9) region of 
TnC. The N-terminal and C-terminal regions are separated by a short linker. The C-
terminal region of TnC interacts with TnI and TnT but is not involved directly with 
calcium dependent regulation of contraction 69,70. The metal binding sites in the C-
terminal domain are high affinity and low specificity. Under physiological conditions, 
these sites are nearly always filled with either magnesium or calcium 71. The C lobe of 
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TnC interacts with the C-terminal of the IT coiled coil. Residues 259, 263, 266, 267, and 
270 of H2(T2) interact with loop 3 (residues 101, 102, 105, 109 and 111) and loop 4 
(residues 149, 150, and 151). A hydrogen bonds forms between residue 270 (Asp) of 
TnT and residue 111 (Tyr) of TnC and also between residue 266 (Asn) of TnT and 
residue 109 (Asp) of TnC. The 111 Tyr residue and 109 Asp of TnC coordinates calcium 
to loop 3 55. This suggests that metal (calcium or magnesium) binding to the TnC C lobe 
functions in maintaining the interaction of TnT and TnC. The C lobe of TnC is therefore 
closely associated with the IT coiled coil regardless of physiological calcium 
concentration. In the cardiac isoform of TnC, the N-terminal domain contains a defunct 
EF hand that does not bind metal. The functioning EF hand in the N-terminal domain is 
a low affinity site that is highly specific to calcium binding. Calcium concentration 
dependence of binding to this N-terminal EF hand functions in regulating contraction. 
Calcium (2 Ca2+ in skeletal and 1 in cardiac muscle) can only bind the N-terminal EF 
hand at high physiological calcium concentrations allowing troponin C to switch 
conformations based on calcium concentration. 
 
Figure 9: Schematic of Troponin C showing locations of interactions (A) and important 
regions (B) 57 
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The interaction of the IT coiled coil and TnC C lobe does not change with calcium 
concentration. The C-terminal of TnT (residues 272-288) and TnI (residues 137-210) 
which are located very close to that region must move significantly in a calcium 
dependent manner 55. The binding of calcium to the N-terminal lobe of TnC is thought to 
open a hydrophobic pocket on TnC. The H3(I) helix of TnI (residues 150-159) known as 
the regulatory domain (or regulatory region or switch region) is pulled into this 
hydrophobic region of the TnC N lobe (Figure 10) 72. The conformational change 
associated with movement of the switch segment is thought to lower the affinity of the 
adjacent inhibitory region (residues 137-148) and C-terminal region (residues 169-210) 
of TnI for actin-tropomyosin 55. The troponin complex therefore becomes less 
associated with actin via removal of the TnI-actin-tropomyosin interaction. It is believed 
this diminished interaction of troponin with actin allows tropomyosin to move to a 
position that promotes myosin binding and activity.  
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Figure 10: Schematic diagram of the core domain of troponin illustrating subunit 
domains and responses to calcium55.TnT (yellow), TnI (blue/light blue), TnC (red), 
tropomyosin (orange), actin (green). 
 
The interaction of TnC with TnI and TnT is enhanced by high calcium 
concentration. This enhanced association with TnC causes TnI to weaken its interaction 
with actin and TnT to weaken its interaction with actin-Tm. These changes in affinity 
may be responsible for calcium induced movement of tropomyosin along actin by 
freeing restraints placed on tropomyosin by troponin.  
Conservation of the amino acid sequences of each of the troponin subunits is 
important for maintaining the interactions described. It is clear that modifications to the 
primary structure of any of the troponin subunits can strengthen or weaken these 
interactions. Some of the known effects of changes to the primary structure of troponin 
are described below. 
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Cardiomyopathies Result from Changes to Troponin Primary Structure 
Changes to the primary structure of troponin subunits can lead to 
cardiomyopathies by changing the calcium sensitivity, force generation, crossbridge 
cycling rate, and calcium cooperativity of the actin regulatory complex. Each of these 
changes can be explained by changes in the equilibrium of the actin state distribution 
between the blocked (B), closed (C) and open (M) states. Modifications to the primary 
structure can come from different isoforms, phosphorylation or mutations. Mutations 
have been found to be capable of increasing or decreasing the population of any of the 
three actin states. Many of these mutations have also been shown to be associated with 
cardiac diseases 1,73. An understanding of how these mutations affect calcium 
sensitivity, force generation, crossbridge cycling rate, and calcium cooperativity of the 
actin regulatory complex is necessary for identification of better therapies and potential 
cures for those afflicted.  
 Over 100 cardiomyopathy causing troponin mutations have been identified and 
characterized in a variety of ways to probe their effects on calcium sensitivity, force 
generation, crossbridge cycling rate, and calcium cooperativity. Comparing the state 
distributions of actin regulated by wild type troponin to actin regulated by mutant 
troponin is the ideal method of identifying important troponin residues. However, of the 
many mutations so far identified, few have fully characterized state distributions. Most 
troponin mutation have been characterized in regard to their effect on calcium 
sensitivity. Tables 1-3 summarize mutations of troponin subunits that have been linked 
to cardiomyopathies. See Lu et. al 2013 74 for further information on each disease 
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causing mutation of troponin. The calcium sensitivity is related to the state distribution 
but does not fully describe the distribution between three states. It is however, a useful 
parameter for identifying important regions of the troponin complex and regions that 
need further characterization.  
 
Table 1: Calcium Sensitizing Troponin Mutation Effects and Associated Disease 
Disease Mutant 
HCM I79N, R92Q, R92L, R92W, R94L, A104V, R130C, ΔE160, 
E163R, E163K E244D, R278C, R278P, Δ28(+7), Δ14 TnT 
R145G, R145Q, R162W, ΔK183, D190G*, G203S, K206Q TnI 
A8V, A31S, C84Y, D145E TnC 
DCM  
RCM ΔE96 TnT 
L144Q, R145W, A171T, K178E, D190G*, R192H TnI 
NA N100/E101 TnT,  
*D190G causes both HCM and RCM. 
*R146G and R146W has increased activity at low calcium and decreased activity at 
high calcium 
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Table 2: Calcium Desensitizing Troponin Mutations and Associated Disease 
Disease Mutant 
HCM  
DCM R131W, R141W, ΔK210, R205L, D270N TnT 
K36Q, N185K TnI 
E59D, D75Y, Y5H M103I, G159D TnC 
RCM  
NA T206 TnT 
S23, S24, S43E, S45E, T144E TnI 
 
Table 3: Troponin Mutations That Do Not Effect Calcium Sensing 
Disease Mutant 
HCM E134D, L29Q TnC 
DCM A2V, P16T TnI 
RCM I79N, E136K TnT 
NA S23, S24, S43, S45, T144, R146G*, R146W* TnI 
 
 An interesting effect on the state distribution was observed for the ∆14 mutation 
of troponin T in our lab. The ∆14 mutation of TnT, missing the last 14 residues of the C-
terminal, was found to eliminate the blocked state and stabilize the open state. This 
finding reveals an important function of the C-terminal of troponin T previously 
unrecognized. The last 14 residues of troponin T are necessary for fully inactivating the 
myosin ATPase at low calcium and for preventing full activation at high calcium. Known 
interactions of this C-terminal region of troponin T are notably absent. Crystal structures 
of the core domain of troponin, as described above, showed that this C-terminal region 
of troponin does not interact with other troponin regions. This suggests that the region is 
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either intrinsically disordered or requires actin or tropomyosin presence to assume a 
structure. 
 Further characterization of this region of troponin T is important as it is in an 
unannotated portion of the troponin T amino acid sequence and may contain a 
previously unknown but important interaction. To further characterize this region, we 
wish to identify which of the last fourteen residues contribute to maintaining the blocked 
and open states. To do this, we generated a set of C-terminal truncation mutants 
missing varying numbers of C-terminal residues. Experimental analysis of these 
truncation mutants will allow us to calculate state distributions for each. Residues 
important in maintaining the blocked and open states can be inferred from differences 
between adjacent truncation mutants. 
Various methods have been developed for probing the actin state to identify how 
primary structure modifications affect the actin state distribution. One method measures 
ATPase activity in the absence and presence of calcium. The ATPase activity correlates 
with the crossbridge cycling rate and is a direct functional measure of the population of 
the open (M) state. A mutation that stabilizes the open (M) state will have increased 
ATPase activity in both the absence and presence of calcium. A mutation that stabilizes 
the blocked (B) state will have decreased ATPase activity in both the absence and 
presence of calcium. A mutation that stabilizes the closed (C) state will have increased 
ATPase activity in the absence and decreased activity in the presence of calcium. Other 
methods of quantifying state distribution measure rates of transitions between states in 
the absence and presence of calcium. In these methods, actin, tropomyosin or troponin 
are often tagged with fluorescent probes to allow visualization of structural changes 
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associated with different actin states 24,75,76. The methods that our lab utilizes to 
measure state distributions are described in Chapter 2.
 Chapter 2: Experimental Methods 
Protein Preparation 
Skeletal actin, skeletal myosin, skeletal myosin S1, bovine cardiac ether powder, bovine 
cardiac troponin, bovine cardiac tropomyosin, human cardiac troponin C, human cardiac 
troponin I, human cardiac troponin T, and reconstituted human cardiac troponin was 
prepared by a standard method [Appendix C: Protein Preparation]. Mutations of 
troponin T were prepared by Dr. Bill Angus. Acrylodan labelling of tropomyosin and 
pyrene labelling of actin was performed using a standard method. Verification of 
troponin and tropomyosin purity was completed using SDS PAGE gels with a molecular 
weight marker Protein concentrations were determined photometrically or using a Lowry 
assay [Appendix C: Protein Preparation]. 
 
ATPase Activities 
ATPase rates gives a functional measure of the population of the open (M) state 
of actin. Myosin only exhibits ATPase activity significantly when it is able to bind to actin 
and release its ATP hydrolysis products. This only occurs when actin is in the open (M) 
state and does not occur when actin is in the blocked (B) or closed (C) state. In our 
experiments, the ATPase rate is calculated from the amount of phosphate released by 
myosin S1 at different times in a reaction. The calculated ATPase rate is normalized to 
give a fraction of actin in the open (M) state. 
Rabbit skeletal actin and bovine cardiac tropomyosin were allowed to mix in a 7:2 
molar ratio at least twelve hours. All experimental solutions contained 10 µM Actin, 2.86 
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µM tropomyosin, 1 mM 32P labeled ATP, and 0.1 µM Rabbit skeletal myosin S1. Each 
troponin mutant was separately incorporated into the reaction mixture at either 2.86 µM 
or 2.14 µM. The reaction buffer contained 34 mM KCl, 10 mM MOPS pH 7, 3 mM 
MgCl2, 0.5 mM CaCl2, and 1 mM DTT. All solutions were 1 mL final volume and 
prepared in 4 mL Teflon beakers. Preparing reaction solutions, actin, tropomyosin and 
troponin were first allowed to mix five minutes on ice. The reaction mixture was moved 
to a water bath set to 25 degrees C over a stir plate and allowed to equilibrate one 
minute. 32P ATP was added next and allowed to mix one minute. The reaction was 
initiated upon addition of Myosin S1. 
The following steps were completed subsequently without pause. At four different 
time points during the reaction, 200 µL were removed from the reaction mixture and 
added to 0.4 ml of 1.5 N HCl, 1.5 mM NaPO4. 0.2 ml of 1.4 N H2SO4, 4.3% 
Silicotungstic acid were added followed by one second vortex mixing. One mL of 1:1 
isobutanol:benzene was added followed by 0.2 ml of 5% ammonium molybdate. The 
mixture was then vortex mixed for exactly thirty seconds. The generation and movement 
of free phosphate in the process is summarized in Figure 11. 
 
Figure 11: ATPase Experiment Scheme 
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The first four time points were within the first fifteen minutes of the reaction. A 
fifth sample was taken after complete ATP hydrolysis once per day to determine the 
radioactivity dependent end point of the reaction (Countinfinity) for use in rate calculations. 
After all samples have been allowed to rest for at least two minutes after the final thirty 
second vortex mixing, 200 µL were taken from the organic (top) phase of each sample 
and placed into scintillation tubes. To each scintillation tube, 4 mL of ecolite scintillation 
fluid was added. The total counts for each tube were measured in a scintillation counter. 
 The purpose of the HCl is to lower the pH and stop the reaction. The Pi in NaPO4 
functions to help extract the 32Pi. The silicotungstic and sulfuric acid precipitate the 
proteins to keep them in the aqueous layer. The molybdate functions to complex with 
the released Pi. The butanol-benzene is present to provide an organic layer to extract 
and isolate the phosphomolybdate complex. 
The scintillation count is plotted for each time point (in seconds) and the slope of 
the plot is calculated. The rate is calculated from the slope and Countinfinity using 
equation 1. 
 
Equation 1:    ATPase Rate (per second) =  
slope∗1000
0.1 µM S1∗Countinfinity
 
 
In order to convert ATPase rates into changes of state populations, the rates are 
normalized at a particular condition to the minimum possible rate (vmin) and to the 
maximum possible rate (vmax; note that this is distinct from VMax, the rate at saturating 
actin and ATP). The value of vmax is the rate at any defined [ATP] and [actin] when all of 
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the actin is in the M state. Similarly, vmin is the rate at any defined [ATP] and [actin] 
when all of the actin is in the B state. 
The fraction of actin in the open (M) state is given by equation 2 where vobs is the 
observed rate and vmin is the rate for actin regulated by S45E TnI containing troponin 
when calcium is chelated. 
 
Equation 2: Fraction in Open State:  
(vobs−vmin)
(vmax−vmin)
 
 
The vmin can be estimated from the observed rate for wild type troponin as 
shown previously using equation 377. 
 
Equation 3: vmin = 0.61 x vobs,wild type,EGTA 
 
vmax is the average of rates obtained for actin regulated by different troponin 
mutants in the presence of calcium and stabilized by NEM-S1 crossbridges. To 
measure the vmax a small amount of NEM-S1 and an equivalent molar excess of actin is 
added prior to an ATPase experiment at high calcium and allowed to incubate and form 
crossbridges with actin prior to initiation of the experiment. Although the NEM-S1 does 
not exhibit significant ATPase activity itself, it binds tightly to actin and holds 
tropomyosin in a position that allows unmodified S1 to bind more readily. This 
experiment is used as a measure of the ATPase activity when actin is considered 100% 
in the open state. Comparing the ATPase rate of actin regulated by each troponin 
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variant to the corresponding rate in the presence of NEM-S1 we can calculate actual 
population of actin in the open state. 
Stopped Flow Kinetics 
 Stopped flow kinetic measurements permit monitoring of reactions from less than 
two milliseconds after mixing. Reactions can be monitored if there is a difference in 
absorbance, light scattering, or fluorescence as a result of reaction or different 
components of a mixture. Fluorescent probes are often utilized to produce a difference 
in signal between certain states of a reaction to allow the transition to be observed. 
Two solutions are loaded into syringes, then injected into cells. Upon reaction 
initiation, a volume within each cell is rapidly pumped through a mixer then into a 
cubical reaction cell. Light of a specified wavelength is emitted through one edge of the 
cell. Transmittance of the specified wavelength of light through the sample is measured 
out of the opposite side of the cell. Fluorescence or light scattering are measured at a 
right angle to the path of the emitted light. A schematic of the stopped flow apparatus is 
shown in Figure 12. 
 
Figure 12: Schematic of stopped flow apparatus 
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ATPchase Experiment 
In the ATP chase experiment, ATP is rapidly mixed with regulated actin held in 
the fully open (M) state by formation of myosin crossbridges. Reaction solution one 
contains the proteins actin, tropomyosin, troponin, and myosin S1 in a 7:2:2:7 molar 
ratio. The tropomyosin is fluorescently labeled with an acrylodan probe on cysteine-190. 
Figure 13 shows the location of cysteine-190 along tropomyosin relative to actin and 
troponin. Figure 14 shows the chemical structure of the acrylodan probe. The solution is 
excited with light of 391 nm wavelength and observed through a 435/451/460 filter.  
 
 
Figure 13: Schematic of the core domain of troponin located on tropomyosin and actin. 
The star indicates the location of cysteine-190 on tropomyosin that is labelled with 
acrylodan 
 
Figure 14: Chemical Structure of Acrylodan Probe 
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Reaction solution two contains ATP in the same buffer as solution 1. After 
mixing, the final concentration of ATP is 1000 fold greater than the actin and myosin S1 
concentration. Since ATP significantly decreases the affinity of myosin S1 for actin, the 
myosin S1 crossbridges rapidly detach from actin. Upon elimination of the crossbridges, 
actin is no longer stabilized in the fully open (M) state. 
For wild type troponin regulated actin with calcium chelated to EGTA, a rapid 
fluorescence decrease is observed followed by a slower fluorescence increase [Figure 
15]. It is believed that these two transitions correspond to transitions between the three 
structural states of regulated actin. The rapid initial decrease in fluorescence is 
attributed to the transition from the open (M) to closed (C) state. The slower increase in 
fluorescence is attributed to the closed (C) to blocked (B) transition. 
31 
 
 
Figure 15:ATPchase experiment of actin regulated by wild type troponin 
 
The amplitude of the closed to blocked state transition can be normalized relative 
to the wild type transition amplitude using equation 4. 
 
Equation 4: Normalized Amplitude =  
ampobs
ampWT
 
 
The normalized amplitudes for actin regulated by troponin variants tells us how a 
troponin variant effects the stability of the blocked state as summarized in Table 4. 
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Table 4: Mutation Effect on Blocked State 
Relative Amplitude Blocked State 
Greater than one Stabilized 
Equal to one Unaffected 
Less than one Destabilized 
Zero Absent 
 
Rabbit skeletal actin and bovine cardiac tropomyosin were allowed to mix in a 7:2 
ratio at least twelve hours. Solution 1 contained 2 µM Actin, 0.86 µM tropomyosin, 0.86 
µM troponin, and 2 µM Rabbit skeletal myosin S1. Solution 2 contained 2 mM ATP. The 
reaction buffer contained 152 mM KCl, 20 mM MOPS pH 7, 4 mM MgCl2, 2 mM EGTA, 
and 1 mM DTT. Each solution was about 1.4 mL in volume and prepared in 4 mL Teflon 
beakers. The actin-tropomyosin solution was mixed with troponin on ice and allowed to 
incubate at least five minutes before loading into stopped flow. Upon mixing solution 1 
and 2 in equal parts in the stopped flow, the final concentrations of each protein in the 
reaction mixture were halved. 50 mM ATP stocks were either made fresh or thawed 
immediately before use. All stopped flow experiments were completed at 10 degrees 
Celsius. Solutions were allowed to equilibrate in temperature for two minutes upon 
injection into cells before mixing. 
 
S1 Binding to Actin 
 In the S1 binding experiment, myosin S1 was rapidly mixed with regulated actin 
(Actin-tropomyosin-troponin) in a stopped flow apparatus. Reaction solution one 
contained the proteins actin, tropomyosin, and troponin in a 7:2:2 molar ratio. The actin 
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was fluorescently labeled with a pyrene probe on cysteine-374 [Figure 16, Figure 17]. 
The solution was excited with light of 365 nm wavelength and observed through a 
Schott 51270 filter. 
 
 
Figure 16: The structure of F-actin indicating the position of cysteine-374 to which 
pyrene is attached78. 
 
 
Figure 17: Chemical Structure of the pyrene probe attached at cysteine-374 of actin 
 
Reaction solution 2 contained myosin S1 in the same buffer as solution 1. After 
mixing, the final concentration of myosin S1 was 5 fold lower than the actin 
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concentration. The rate of myosin binding to actin is proportional to the distribution of 
regulated actin states. There is debate as to the rates at which myosin S1 binds to the 
different states of actin, however, there is general agreeance that myosin S1 binds 
fastest to the open (M) state and slowest to the blocked (B) state. By combining results 
at both low and high calcium concentration, qualitative information regarding effects on 
actin state distribution can be inferred [Table 5]. 
 
Table 5: Evidence from S1 Binding Experiment on State Distribution 
Relative Rate in EGTA* Relative Rate in Calcium* State Distribution 
Faster Faster Stabilized Open State 
Slower Slower Stabilized Blocked State 
Faster Slower Stabilized Closed State 
Slower Faster Destabilized Closed State 
*Relative to Wild Type Regulated Actin 
 
Furthermore, if the population of the open (M) state is known from ATPase 
experiments, the actual state distribution of the blocked (B) and closed (C) state can be 
quantified. The fraction in the closed (C) state can be calculated using equation 6 
 
Equation 6: Fraction C state =
KB∗(1−M)
1+KB
 
 
M is the fraction of actin in the open (M) state as determined by ATPase 
experiments. KB is calculated from equation 7. 
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Equation 7:   KB =  
1
kcalcium
kEGTA
−1
 
 
 With the fraction of the open (M) and closed (C) state known, the fraction in the 
blocked (B) state can be calculated from equation 8 where C is the fraction in the C 
state. 
 
Equation 8:   Fraction B state = 1 − C − M 
 
For wild type troponin regulated actin with calcium chelated to EGTA, a decrease 
in fluorescence is observed upon addition of myosin S1 [Figure 18]. Before addition of 
myosin S1 under low calcium conditions, actin is about 60% in the blocked state and 
about 40% in the closed state; very little actin is in the open state. It is believed that the 
fluorescence change corresponds to a transition from a mixture of the three structural 
states of regulated actin in the absence of crossbridges to a mixture of the closed (C) 
and open (M) states in the presence of crossbridges. In order to infer effects of 
mutations on the actin state distribution S1 binding experiments must be completed at 
both low and high calcium conditions. 
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Figure 18: S1 Binding experiment using actin regulated by wild type troponin 
 
For wild type troponin regulated actin in the presence of calcium, a faster 
decrease in fluorescence is observed compared to the experiment where calcium is 
chelated by EGTA. This is true because calcium removes troponin induced myosin 
ATPase inhibition and destabilizes the blocked state resulting in higher populations of 
the closed (C) and open (M) states to which myosin S1 more readily binds.  
 Chapter 3 Truncation Mutant Results and Discussion 
 
Part 1: Identification of the residues within the C-terminal region of troponin T that are 
responsible for forming the blocked (B) state at low Ca2+. 
 
Three lines of evidence support the view that deletion of the 14 C-terminal 
residues of TnT eliminates the blocked state. First, there is an increase in ATPase 
activity at low Ca2+ for ∆14 TnT containing regulated actin filaments79. The loss of the 
blocked state would lead to redistribution between the closed and open states resulting 
in an increase in the open state. Second, deletion of the 14 terminal residues of TnT 
eliminates the increase in acrylodan-tropomyosin fluorescence following the rapid 
dissociation of S1-ATP from regulated actin79. Third, a lag in the equilibrium binding of 
myosin S1 to actin in EGTA was found to be absent when regulated by ∆14 TnT80. 
To identify the residues within the C-terminal region of TnT that are responsible 
for forming the blocked state at low calcium, acrylodan tropomyosin and pyrene actin 
fluorescence changes were measured for actin regulated by wild type troponin and 
truncation mutants. 
ATPchase data were collected for actin regulated with tropomyosin and each of 
six troponin variants containing wild type or truncated troponin T mutants: ∆4, ∆6, ∆8, 
∆10, or ∆14. Average fluorescence time courses are shown in Figure 19 for actin 
regulated by each troponin mutant. A rapid decrease in fluorescence voltage is shown 
in the first 0.02 seconds for all traces. This initial decrease corresponds to a transition 
from the open (M) state to the closed (C) state. A slower increase in fluorescence 
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occurs after about 0.02 seconds and plateaus around 0.5 seconds for all traces with the 
exception of the ∆14 TnT trace. This increase corresponds to a transition from the 
closed (C) state to the blocked (B) state.  
 
Figure 19: Time course of transition from the open to the closed and blocked state 
measured by acrylodan tropomyosin fluorescence. At zero time, 2 µM skeletal actin, 2 
µM skeletal S1, 0.86 µM bovine cardiac acrylodan tropomyosin, and 0.86 µM human 
cardiac troponin (WT, ∆14, ∆4, or ∆6 TnT reconstitution) were rapidly mixed with 2 mM 
ATP. Conditions: 90 mM KCl, 20 mM Mops, 4 mM MgCl2, 2 mM EGTA, 1 mM DTT. 
Filter: 435/451/460. 10°C. 391 nm excitation. At least three runs were averaged for each 
trace shown.  
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The difference between the amplitude at the minimum and the plateau at 0.5 
seconds was used as a functional measure of the blocked state population. The 
amplitude difference was calculated for actin regulated by each troponin variant and 
normalized to one with respect to wild type troponin regulated actin Figure 20 
 
Figure 20: Amplitude of transition from the closed to the blocked state measured by 
acrylodan tropomyosin fluorescence. Points represent an average of at least four runs. 
At zero time, 2 µM skeletal actin, 2 µM skeletal S1, 0.86 µM bovine cardiac acrylodan 
tropomyosin, and 0.86 µM human cardiac troponin (WT, ∆14, ∆4, ∆6, ∆8 or ∆10 TnT 
reconstitution) were rapidly mixed with 2 mM ATP. Conditions: 90 mM KCl, 20 mM 
Mops, 4 mM MgCl2, 2 mM EGTA, 1 mM DTT. Filter: 435/451/460. 10°C. 391nm 
excitation. The C-terminal sequence of TnT: NH2-…SKTRGKAKVTGRWK-CO2H. 
 
In the ATPchase experiment, the amplitude of the closed (C) to blocked (B) 
fluorescence change varied depending on the troponin variant. As observed previously 
81, the trace for actin regulated with ∆14 TnT had a normalized amplitude of zero (Figure 
20). This absence of transition was attributed to a complete or near complete loss of the 
blocked (B) state. This supports the evidence from the ATPase data for ∆14 TnT 
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regulated actin that enhancement of the open state is a result of redistribution from the 
blocked state81. 
Our ATPchase data for actin regulated by troponin containing WT TnT and the 
variants ∆4, ∆6, ∆8, and ∆10 all exhibit normalized amplitudes that fall between that of 
wild type and ∆14 TnT regulated actin. As there is a decrease in normalized amplitude 
as residues are removed from the C-terminus, this experiment suggests that many or all 
of the fourteen C-terminal residues serve an important role in maintaining the blocked 
(B) state. We utilized one other experiment to measure the rate of binding of myosin S1 
to actin. When measured at both low and high calcium, this method provides an 
alternative means of measuring the distribution between the blocked and closed state. 
The myosin S1 binding to actin experiment monitors the fluorescence change of 
a pyrene probe on actin. Raw data from this experiment are shown in Figure 21. This 
experiment was completed in the absence of calcium for actin regulated by wild type, 
A8V/∆14, ∆6, ∆8 or ∆10 TnT troponin. The A8V/∆14 troponin variant was used as 
control for actin stabilized in the open state and will be discussed further in chapter 5. 
Note that this experiment is completed with myosin S1 in excess. In the latter studies, 
actin is used in excess. Differences in the rate of S1 binding can be measured by either 
method82, however, this experiment was completed with S1 in excess in the interest of 
conserving troponin.  
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Figure 21: Time course of pyrene-labeled actin fluorescence changes upon S1 binding 
in the absence of ATP and absence of calcium.0.4 µM skeletal pyrene actin, 0.17 µM 
bovine cardiac tropomyosin, 0.17 µM human cardiac troponin (WT, A8V/∆14, ∆6, ∆8 or 
∆10 TnT reconstitution) were mixed at time zero with 4 µM rabbit skeletal S1. 
Conditions: 152 mM KCl, 20 mM Mops, 4 mM MgCl2, 2 mM EGTA, 1 mM DTT. Filter: 
370/400/475nm, 10°C, 365 nm excitation.  
 
The rate of the decrease in fluorescence reflects the rate of binding of myosin S1 
to actin. The rates of the initial rapid fluorescence decrease are plotted in Figure 22. 
The rate of binding of myosin S1 to wild type troponin regulated actin was the lowest at 
about 2.5/sec. The binding to actin held in the open state by A8V/∆14 was the highest at 
about 4.1/sec. Actin regulated by the truncation mutant ∆6 TnT troponin exhibited a rate 
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of about 3.1/sec whereas actin regulated by ∆8 or ∆10 TnT troponin exhibited a slightly 
faster rate of about 3.4/sec.  
A lag in the rate of fluorescence decrease from this experiment for wild type 
troponin regulated actin is also observed. The lag appears to be diminished for actin 
regulated by the A8V/∆14 mutant. This diminished lag may also be evidence for loss of 
the blocked state. 
When rates of S1 binding to actin are obtained at both high and low calcium, the 
state distribution between the blocked and closed state can be calculated. This 
calculation is based on the assumption that myosin S1 only binds to actin in the closed 
and open states. For this reason, we utilized the ATPchase method as our primary 
means of characterizing the blocked state since it is model independent.  
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Figure 22: Rate of pyrene-labeled actin fluorescence changes upon S1 binding in the 
absence of ATP and absence of calcium.0.4 µM skeletal pyrene actin, 0.17 µM bovine 
cardiac tropomyosin, 0.17 µM human cardiac troponin (WT, A8V/∆14, ∆6, ∆8 or ∆10 
TnT reconstitution) were mixed at time zero with 4 µM rabbit skeletal S1. Conditions:152 
mM KCl, 20 mM Mops, 4 mM MgCl2, 2 mM EGTA, 1 mM DTT. Filter: 370/400/475 nm, 
10°C, 365 nm excitation. The C-terminal sequence of TnT: NH2-
…SKTRGKAKVTGRWK-CO2H. 
 
Part 2: Identification of the residues within the C- terminal region of troponin T that are 
responsible for inhibiting formation of the open (M) state at saturating Ca2+. 
Truncations 
 
To identify residues within the C-terminal region of TnT that are responsible for 
forming the open state at saturating calcium, ATPase data were collected for actin 
regulated by wild type troponin and each of the truncation mutants containing ∆4, ∆6, 
∆8, ∆10, or ∆14 TnT. 
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Because of the importance of the ATPase assay in defining the open state, it is 
helpful to review it here. A reaction that hydrolyzes ATP to ADP and inorganic 
phosphate is initiated in a reaction cell. Molybdate is added to the reaction cell after 
some time has passed and complexes with the released inorganic phosphate. The 
phospho-molybdate complex is then extracted into an organic layer using 
butanol:benzene. The butanol benzene layer can be analyzed in a scintillation counter 
to measure the amount of phosphate released. By measuring the amount of phosphate 
release at different time points in the reaction, the rate of ATPhydrolysis (ATPase) can 
be measured. 
ATPase data were collected for actin regulated with tropomyosin and each of six 
troponin variants containing wild type or truncated troponin T mutants: ∆4, ∆6, ∆8, ∆10, 
or ∆14. Each experiment was completed at two different troponin concentrations for 
each troponin variant. A timer was started upon initiation of each reaction with addition 
of myosin S1 and aliquots were removed for analysis after one, four, eight, and twelve 
minutes. Each aliquot was analyzed in a scintillation counter and its count recorded.  
The slopes of plots of time versus scintillation count were calculated for each 
experiment. The slope along with the S1 concentration and count at complete ATP 
hydrolysis were used to calculate the ATPase rates for each experiment [Figure 23].  
The rates were normalized as described [Equation 2] to calculate the fraction in 
the open (M) state for actin regulated by each troponin variant [Table 6]. We used a 
previously determined value for the vmax, 9.7/sec (Franklin 2012). 
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Figure 23: Rate of actin-tropomyosin-troponin activated myosin S1 ATPase activity in 
the presence of Ca2+.  Points represent averages of four or five experiments. 
Conditions: 10 mM skeletal actin, 2.86 mM BvC tropomyosin, 2.86 mM human cardiac 
troponin (WT, ∆14, ∆4, ∆6, ∆8 or ∆10 TnT reconstitution), and 0.1 mM rabbit skeletal S1 
at 25 C in 34 mM KCl, 10 mM MOPS, 3 mM MgCl2, 0.1 mM CaCl2, 1 mM DTT, pH 7. 
The C-terminal sequence of TnT: NH2-…SKTRGKAKVTGRWK-CO2H. 
 
Table 6: Fraction open M state of actin regulated by each truncation mutant 
Troponin Residues 
Removed 
Rate in Ca2+ (1/sec) Fraction M 
State 
WT 0 2.12 0.22 
∆4 4 2.34 0.24 
∆6 6 2.05 0.21 
∆8 8 2.72 0.28 
∆10 10 2.74 0.28 
∆14 14 2.82 0.29 
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Franklin et. al. obtained normalized ATPase rates at high calcium of 0.18 and 
0.29/sec for wild type and ∆14 TnT skeletal troponin regulated actin respectively. At low 
calcium, they obtained normalized ATPase rates of 0.0011 and 0.015/sec for wild type 
and ∆14 TnT skeletal troponin regulated actin respectively. The enhanced ATPase rate 
for ∆14 TnT regulated actin in both the absence and presence of calcium suggested 
activation is primarily a result of loss of the blocked (B) state. At high calcium, we 
obtained similar values of 0.22 and 0.29/sec respectively for wild type and ∆14 TnT 
skeletal troponin regulated actin, respectively.  
For the series of truncation mutants, our ATPase data shows a large difference in 
rate from WT to ∆4 TnT, ∆6 TnT to ∆8 TnT, and ∆10 TnT to ∆14 TnT regulated actin. At 
least three regions of the C-terminal of TnT are important for maintaining the open state. 
The most significant of these regions is the first four residues of the C-terminus. Upon 
removal of the first four residues of the C-terminus, as in the ∆4 TnT mutation, the 
ATPase rate increases to halfway between the WT and ∆14 TnT regulated actin rate. 
Additionally, loss of the seventh and eight residues in the ∆8 TnT mutant (and 
subsequent larger deletions) appear to have a significant effect on the ATPase rate and 
population of the open state compared to the adjacent ∆6 TnT mutant. As evidenced by 
the observation by Franklin et al. at low calcium, we believe the enhancement of the 
ATPase activity and M state population to be a result of redistribution primarily from the 
blocked state.  
These three regions of the C-terminal of TnT will require further characterization 
to confirm this effect. The ATPase experiments should be repeated using different 
troponin preparations to ensure the effect was not a result of differences in the 
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reconstitutions or ratio of subunits. The ∆2 TnT and ∆12 TnT mutant should also be 
characterized in ATPase assays to measure how they affect the open state and to 
identify specific important residues that are required for maintaining the open state. 
Characterizing point mutations in these regions may be useful in identifying whether a 
specific amino acid residue is required for the interaction that maintains the open state.  
 From our ATPase data, we are also able to suggest which C-terminal TnT 
residues are responsible for inhibiting formation of the open, M, state at saturating 
calcium. The TnT regions 274-278, 280-282, and 284-288 each appear to function in 
maintaining the open state of actin. Further characterization of subsequent, intermediate 
and point mutations will allow more accurate identification of the specific residues 
involved. 
 Chapter 4: R146G Results and Discussion 
 
Several laboratories noted that R146G TnI decreased the effect of calcium on 
activity. This reduced regulation occurs because of both an increase in activity at low Ca 
and a decrease in activity at saturating Ca. Mathur et al. used ATPase measurements 
to monitor changes in the distribution of states.  
Mathur et al. concluded that at low Ca2+, the R146G mutation increased the 
fraction of the C state relative to wild type values at the expense of the B state. At 
saturating Ca2+, the R146G mutation increased the fraction of the C state relative to wild 
type values at the expense of the M state. Our current strategy was to use acrylodan 
tropomyosin and pyrene actin probes to measure the extent of stabilization of the closed 
state at low Ca2+ conditions.  
The results of the ATPchase experiment at low calcium for wild type and R146G 
TnI regulated actin are shown in Figure 24. The rapid decrease in fluorescence 
corresponds to a transition from the open M state to the closed C state. No further 
transition occurs in the presence of calcium. The rates of the initial decrease are 354/s 
and 218/s for wild type and R146G TnI containing actin respectively. We attribute this 
difference to a decreased reverse rate constant from the open to closed state for 
R146G TnI regulated actin. 
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Figure 24: The rate of transition from the open, M, state to the closed, C, state in the 
presence of Ca2+ at high ionic strength. Acrylodan-tropomyosin fluorescence changes 
occurred after rapid S1-ATP dissociation. The fluorescence decrease is the transition 
from the open to the closed state. The main figures shows wild type over a long time 
interval. The inset compares the mouse cardiac wild type troponin (curve 1) with mouse 
cardiac R146G TnI containing actin filaments (curve 2). Apparent rates: wild type = 
354/s, R146G = 218/s. Conditions: 2 µM actin, 0.86 µM troponin, 0.86 µM acrylodan 
labeled tropomyosin, 2 µM S1 in 20 mM MOPS buffer pH 7, 4 mM MgCl2, 152 mM KCl, 
0.5 mM CaCl2 and 1 mM DTT was rapidly mixed with 2 mM ATP in 20 mM MOPS buffer 
pH 7, 4 mM MgCl2, 152 mM KCl, 0.5 mM CaCl2 and 1 mM DTT at 10°C. 
 
 The results of ATPchase experiments at high calcium for wild type and R146G 
TnI regulated actin at different ionic strengths are shown in Figure 25. The initial 
decrease corresponding to a transition from the open to closed state is very rapid and 
differences between wild type and R146G TnI could not be measured. The subsequent 
increase in fluorescence corresponds to a transition from the closed to the blocked 
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state. At all three ionic strengths used, the amplitude of the transition for R146G TnI 
regulated actin is lower than that of wild type regulated actin. This suggests that less 
actin transitioned from the closed state to the blocked state. That is, the equilibrium 
constant defining the distribution between the closed and blocked states was shifted 
toward the closed state. 
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Figure 25: The rate of transition from the open, M, state to either the closed, C, state 
(fluorescence decrease) or blocked, B, state (acrylodan fluorescence increase) at low 
Ca2+.Curve 1, wild type actin filaments; Curve 2, actin filaments with R146G TnI. A. At 
the same conditions as Figure 24 (152 mM KCl) but in EGTA, the apparent rates of the 
first phase were 449/s and 401/s for wild type and R146G, respectively. The apparent 
rates for the slow phase were wild type = 15/s, R146G = 59/s. B. At 90 mM KCl the 
apparent rates for the slow phase were: wild type = 13/s, R146G = 27/s. C. At 30 mM 
KCl the apparent rates for the slow phase were: wild type = 13/s, R146G = 15/s. D. 
Fluorescence amplitudes for regulated actin containing wild type (solid circles) and 
R146G TnI (open circles) as a function of the square root of the ionic strength. The solid 
lines are best fits to the data. The dashed line is a theoretical curve for a constant ratio 
of mutant to wild type amplitudes of 0.27. Conditions: 2 µM actin, 0.86 µM troponin, 0.86 
µM tropomyosin, 2 µM S1 in 20 mM MOPS buffer pH 7, 4 mM MgCl2, 2 mM EGTA and 
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1 mM DTT was rapidly mixed with 2 mM ATP in 20 mM MOPS buffer pH 7, 4 mM 
MgCl2, 2 mM EGTA and 1 mM DTT at 10°C. 
 
To confirm these results we utilized a popular method of estimating changes in 
the population of the blocked state based on the kinetics of myosin S1 binding to actin. 
Results of the S1 binding experiment for wild type and R146G TnI regulated actin at 
high and low calcium is shown in Figure 26. At high calcium, the traces for wild type and 
R146G TnI regulated actin are nearly indistinguishable with rates of 0.38 and 0.37/s 
respectively. This corresponds to a similar rate of S1 binding to the closed and open 
states of actin. At low calcium, the rate of S1 binding to R146G TnI regulated filaments 
is 0.27/sec compared with 0.14/sec for wild type TnI regulated actin. The higher rate of 
binding of S1 to R146G TnI regulated corresponds to an increased population of the 
closed and/or open state. Since no significant difference was observed in the traces at 
high calcium, the increased rate of S1 binding at low calcium is likely the result of 
stabilization of the closed state.  
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Figure 26: Rate of binding of rigor S1 to pyrene labeled actin filaments containing 
tropomyosin and troponin at saturating Ca2+ (A) or at very low Ca2+ (B). Curve 1, wild 
type actin filaments; Curve 2, actin filaments with R146G TnI. Apparent rates with 
standard deviations in the presence of Ca2+: wild type = 0.38 +/- 0.004/s, R146G = 0.37 
+/- 0.007/s. Apparent rates at low Ca2+: wild type = 0.14 +/- 0.003/s, R146G = 0.27 +/- 
0.007/s. Conditions: 2 µM phalloidin stabilized pyrene actin, 0.86 µM tropomyosin 0.86 
µM troponin in a buffer containing 152 mM KCl, 2 mM EGTA, 20 mM MOPS buffer pH 
7, 4 mM MgCl2, 1 mM DTT was rapidly mixed with 0.4 µM myosin S1 in 152 mM KCl, 2 
mM EGTA, 20 mM MOPS buffer pH 7, 4 mM MgCl2, 1 mM DTT at 10°C. 
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Using the M state populations at high and low calcium from Mathur et. al., the 
fraction of actin in each of the three states was calculated from ATPchase and S1 
binding data [Table 7].  
 
Table 7: Estimated distributions of states of actin-tropomyosin-troponin 
 MATPasea CAcrylodana BAcrylodana  CPyrenea BPyrenea 
wild type Ca2+ 0.33b ≈ 0.67c ≈ 0c - - 
R146G Ca2+ 0.09b ≈ 0.91c ≈ 0c - - 
wild type EGTA 0.014b - - 0.37d 0.62d 
R146G EGTA 0.028b 0.80e 0.17e 0.69d 0.28d 
aThe subscript identifies the method used for estimating the fractions of the open, M, 
closed, C, and blocked, B, states. 
bMathur {Mathur, 2009 #7031}, 33 mM NaCl 
cDetermined from Figure 25 at 152 mM KCl 
dDetermined from Figure 26 at 152 mM KCl using conservation of mass and the 
estimated value of KB from the equation for the case where KT is small 82; KB = 
1/(kCa2+/kEGTA -1). KB = [C]/[B] at equilibrium.  
eDetermined from ratio of acrylodan fluorescence changes in Figure 25 and an estimate 
of the wild type occupancy of the B state obtained from pyrene actin 
measurements in Figure 26.  
 
Van Eyk et al. (1988) investigated the skeletal troponin I inhibitory domain by 
measuring the effects of a series single glycine substituted peptide analogs on the 
ATPase activity. The peptide analogs corresponded to residues 137-148 of cardiac 
troponin I. They were able to identify the effects of individual residues of the TnI 
inhibitory region essential for inhibition. They found the peptide containing the R146G 
mutation produced only 13% inhibition compared to 48% inhibition for the wild type 
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sequence. This agrees with our evidence that shows incorporation of the full R146G 
protein produces a higher ATPase rate at low calcium than wild type troponin I. 
 Chapter 5: A8V Results and Discussion 
 
Previous studies showed that incorporation of the A8V TnC mutant into regulated 
actin filaments increased the ATPase activity at saturating Ca2+ (Landstrom 2008 ) and 
low Ca2+. We were interested in this mutant because, like ∆14 TnT, it increased the 
degree of activation and might operate in a same manner. Specifically, we wished to 
determine if this mutation eliminated the B state and if it stabilized the M state.  
We also wished to determine if a double mutant containing both A8V TnC and 
∆14 TnT exhibited an additive effect on increasing the degree of activation. It would be 
very helpful in our research to be able to fully stabilize the open state. By characterizing 
the open state we could more readily define the concentration of the open state in a 
mixed distribution of states. Our hope was that a double mutant would fully stabilize the 
open state. Our current strategy was to use acrylodan tropomyosin and pyrene actin 
probes to measure the extent of elimination of the B state and stabilization of the M 
state by these mutants. 
 The results from ATPchase experiments at high calcium with actin regulated by 
wild type, A8V TnC, A8V/∆14, or ∆14 TnT Troponin are shown in Figure 27. The initial 
fluorescence decrease corresponds to a transition from the open state to the closed 
state of actin. The subsequent fluorescence increase corresponds to a transition from 
the closed state to the blocked state. The closed to blocked state transition for wild type 
troponin regulated actin has an amplitude of about 0.14. We use this as the standard to 
which the other traces are compared to measure mutations effects on population of the 
blocked state. The trace for A8V TnC regulated actin is nearly indistinguishable from 
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that of wild type with an amplitude of 0.14 as well. This suggests that A8V TnC does not 
affect the blocked state of actin. The trace in Figure 27 for ∆14 does not exhibit any 
detectable fluorescence increase corresponding to a closed to blocked transition as 
discussed previously. The A8V/∆14 double mutant trace, similar to the ∆14 trace, does 
not exhibit any fluorescence increase to the blocked state. This shows that the A8V 
mutant does not recover the blocked state removed by the ∆14 TnT mutant.  
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Figure 27: The rate of transition from the open, M, state to either the closed, C, state 
(fluorescence decrease) or blocked, B, state (acrylodan fluorescence increase) at low 
Ca2+.Curve 1, wild type actin filaments; Curve 2, actin filaments with A8V TnC; Curve 3, 
actin filaments with A8V TnC and ∆14 TnT; Curve 4, actin filaments with ∆14 TnT. The 
apparent rates for the slow phase were: wild type = 7.38/s, A8V = 7.27/s. The 
amplitudes of the transition from the closed to blocked state were: wild type = 0.146, 
A8V = 0.107. The slow phase transition was not detected for ∆14 TnT or the A8V TnC - 
∆14 TnT double mutant. Conditions: 2 µM actin, 0.86 µM troponin, 0.86 µM 
tropomyosin, 2 µM S1 in 90 mM KCl, 20 mM MOPS buffer pH 7, 4 mM MgCl2, 2 mM 
EGTA and 1 mM DTT was rapidly mixed with 2 mM ATP in 90 mM KCl, 20 mM MOPS 
buffer pH 7, 4 mM MgCl2, 2 mM EGTA and 1 mM DTT at 10°C. 
 
The traces for S1 binding to actin regulated by wild type, A8V TnC, A8V/∆14, or 
∆14 TnT Troponin at high and low calcium are shown in Figure 28. The decrease in 
fluorescence is believed to correspond to binding of myosin S1 to actin in the closed 
and open states. The rates of this transition at high and low calcium tell us the stability 
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of the open and closed states relative to the blocked state to which myosin S1 does not 
bind as readily. At high calcium (Figure 28 Panel A), the traces for each troponin variant 
are nearly indistinguishable. The rates for each of those traces are shown in the legend. 
At low calcium (Figure 28 Panel B), the rate of S1 binding to the closed or open 
state of wild type troponin regulated actin (curve 1) is the slowest at 0.139/sec. The 
trace for actin regulated by A8V TnC is very similar to wild type regulation with a rate of 
0.144/sec (curve 2). The traces for actin regulated by ∆14 TnT or the A8V/∆14 double 
mutant troponin (curves 3 and 4) have higher rates of 0.237/sec and 0.222/sec 
respectively. The enhanced rate of S1 binding to actin regulated by A8V TnC suggests 
stabilization of either the closed or open state relative to wild type troponin regulated 
actin. We expected the combination of A8V TnC and ∆14 TnT, which both show 
enhancement in the rate of S1 binding independently, would increase the rate of S1 
binding further than that of ∆14 TnT regulated actin. However, the rate of actin regulated 
by the A8V TnC and ∆14 TnT shows a slightly lower rate of binding. 
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Figure 28: Rate of binding of rigor S1 to pyrene labeled actin filaments containing 
tropomyosin and troponin at saturating Ca2+ (A) or at very low Ca2+ (B).Curve 1, wild 
type actin filaments; Curve 2, actin filaments with A8V TnC; Curve 3, actin filaments 
with A8V TnC and ∆14 TnT; Curve 4, actin filaments with ∆14 TnT. Apparent rates in 
presence of Ca2+: wild type = 0.243/s, A8V = 0.231/s, A8V/∆14 = 0.253/s, ∆14 = 
0.242/s. Apparent rates at low Ca2+: wild type = 0.139/s, A8V = 0.144/s, A8V/∆14 = 
0.222/s, ∆14 = 0.237/s. Conditions: 2 µM phalloidin stabilized pyrene actin, 0.86 µM 
tropomyosin 0.86 µM troponin in a buffer containing 152 mM KCl, 2 mM EGTA, 20 mM 
MOPS buffer pH 7, 4 mM MgCl2, 1 mM DTT was rapidly mixed with 0.4 µM myosin S1 
in 152 mM KCl, 2 mM EGTA, 20 mM MOPS buffer pH 7, 4 mM MgCl2, 1 mM DTT at 
10°C. 
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Our lab also completed ATPase experiments of actin regulated by wild type, A8V 
TnC, ∆14 TnT, and the A8V/∆14 double mutant troponin at both low [Figure 29] and 
high calcium [Figure 30]. At low calcium, wild type regulated actin exhibits the most 
inhibitory function of this set of troponin variants with an ATPase rate of 0.14/sec. Actin 
regulated by A8V TnC was measured to have a slightly higher ATPase rate of 0.15/sec. 
Increases to the ATPase rate at low calcium suggest redistribution of the actin state 
population primarily from the blocked to the open state. Actin regulated by the ∆14 TnT 
mutation showed further stabilization of the open state with an ATPase rate of 0.32/sec. 
Actin regulated by the ∆14 TnT mutation showed even further stabilization of the open 
state with an ATPase rate of about 0.38/sec. In this experiment, it is apparent that the 
A8V TnC and ∆14 TnT troponin variants have an additive effect on the ATPase rate. 
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Figure 29: ATPase activities of bare actin, actin-tropomyosin and actin regulated by 
either WT, A8V TnC, ∆14 TnT, or A8V/∆14 TnT troponin at low Ca2+. Measurements 
were made at 25o C and pH 7.0 in solutions containing 1 mM ATP, 3 mM MgCl2, 34 mM 
NaCl, 10 mM MOPS, 1 mM DTT and 2 mM EGTA. The concentrations of S1, actin and 
tropomyosin were 0.1, 10 and 2.2 µM, respectively. The troponin concentration was 
fixed at 2.8 µM. 
 
 At high calcium, the ATPase rates are significantly higher as calcium removes the 
inhibitory function of troponin. The measured ATPase rate of actin regulated by wild 
type troponin was the lowest measured of the three at 1.9/sec. Actin regulated by A8V 
TnC had a rate of 3.4/sec. Increases to the ATPase rate at high calcium suggest 
redistribution of the actin state population primarily from the closed to the open state. 
Actin regulated by ∆14 TnT troponin was measured to have an ATPase rate of 4.1/sec. 
Actin regulated by the double mutant A8V/∆14 troponin was shown to have the highest 
ATPase rate so far observed from a troponin mutant at 6/sec. This experiment also 
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reveals that the A8V TnC mutant and ∆14 TnT mutant have an additive effect in 
stabilizing the open state. 
 
 
Figure 30: ATPase activities of bare actin, actin-tropomyosin and actin regulated by 
either WT, A8V TnC, ∆14 TnT, or A8V/∆14 TnT troponin at saturating Ca2+. 
Measurements were made at 25o C and pH 7.0 in solutions containing 1 mM ATP, 3 
mM MgCl2, 34 mM NaCl, 10 mM MOPS, 1 mM DTT and 0.1 mM CaCl2. The 
concentrations of S1, actin and tropomyosin were 0.1, 10 and 2.2 µM, respectively. The 
troponin concentration was fixed at 2.8 µM. 
 
 The ATPase vmax was also measured for each of these troponin variants by 
incorporating NEM-S1 as described previously (Chapter 2). The results of that 
experiment are shown in Figure 31. What is notable from this experiment is that even in 
the presence of activating NEM-S1, the ATPase rate of actin regulated by the A8V/∆14 
double mutant does not increase any further than what was observed in the absence of 
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activating NEM-S1. This shows us that actin regulated by A8V/∆14 is nearly 100% in 
the open state. This is significant in that it reveals two possibly interacting sites within 
the troponin complex that are essential in inhibiting the myosin ATPase. It also permits 
a new method of measuring the maximum ATPase activity without the use of myosin S1 
modification. 
 
 
Figure 31: ATPase activities of bare actin, actin-tropomyosin and actin regulated by 
either WT, A8V TnC, ∆14 TnT, or A8V/∆14 TnT troponin at saturating Ca2+ and in the 
presence of NEM-S1.Measurements were made at 25o C and pH 7.0 in solutions 
containing 1 mM ATP, 3 mM MgCl2, 34 mM NaCl, 10 mM MOPS, 1 mM DTT and 0.1 
mM CaCl2. The concentration of S1 was 0.1 µM.10 µM NEM-S1 was included in each 
assay to fully stabilize the open state. The concentrations of actin, tropomyosin and 
troponin were 20, 4.4 and 5.7 µM, respectively to maintain 10 µM free actin. 
 Chapter 6 Discussion 
 
The ∆14 TnT mutation of troponin has been shown to remove an inhibitory state 
and enhance the active state of regulated actin. We repeated and expanded on 
previous studies of this ∆14 TnT troponin mutation by characterizing mutations within 
that C-terminal region. We now show that most of the last fourteen residues of the C-
terminal of TnT appear to function in maintaining the blocked (B) state of regulated 
actin. We also show that three distinct regions of the C-terminal of TnT appear to be the 
most important for maintaining the open (M) state. This evidence comes primarily from 
measurements of ATPase activity and monitoring acrylodan tropomyosin fluorescence 
changes in the ATPchase experiment. 
 Characterizing regions of the troponin complex that are associated with 
cardiovascular diseases is essential in understanding the root cause of the disease and 
is a first step toward finding means of mitigating the disease. The C-terminal region of 
TnT is a potential target for treatment of cardiomyopathies. We know that the C-terminal 
of TnT functions in maintaining both the blocked and the open states of actin. By 
targeting the C-terminal of TnT or its target of interaction, it may be possible to affect 
actin state distribution. The ability to regulate state distribution could be useful in 
treating someone affected by a disease causing mutation. Recognizing means of 
controlling C-terminal TnT interactions requires knowing how the C-terminal operates. 
The first step toward understanding how the C-terminal operates is identifying which of 
the residues of the C-terminal function in forming the blocked state and which function 
in inhibiting the open state. 
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 The C-terminal of TnT is particularly elusive in that we are still unsure whether it 
interacts with any thin filament subunits at all. As described previously, a crystal 
structure of the core domain of troponin, in which the C-terminal of TnT is located, could 
not conclusively identify a binding partner of the TnT C-terminal. The second location of 
interaction of troponin T with tropomyosin (T2) consists of either residues 197-239 of 
TnT 67 or the last sixteen residues of the C-terminal 272-288 57 of TnT. The last sixteen 
residues of the C-terminal of TnT have not been resolved in crystal structures of 
troponin in the calcium saturated state suggesting structural flexibility or interaction with 
actin-tropomyosin55. 
Inhibition of myosin ATPase activity is known to rely on interaction of TnI with 
actin-tropomyosin50,51 to hold actin in the blocked state. The C-terminal region of TnT 
could facilitate the action of TnI by stabilizing the blocked state at low calcium. In order 
to stabilize the blocked state of actin in the absence of calcium, the C-terminal of TnT 
could inhibit the movement of tropomyosin out of an inhibiting position along actin. As 
shown in Figure 32, the C-terminal of TnT is in close proximity to the calcium sensitive 
inhibitory region (IR) of TnI. In the absence of calcium, the mobile domain of TnI and the 
C-terminal of TnT may function together to stabilize tropomyosin in the blocked state 
position. By removing the last fourteen residues of the TnT C-terminal, tropomyosin may 
be allowed to move out of the blocked position more readily regardless of TnI inhibition. 
The C-terminal of TnT could also function to hold actin in the blocked state by 
interacting with tropomyosin itself. The C-terminal of TnT could interact with 
tropomyosin at low calcium to hold tropomyosin in a blocked position along actin 
(Indicated by interaction 1 in Figure 32). If the last fourteen residues of the C-terminus 
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function to hold tropomyosin in a blocked position along actin, we would expect 
removing those last fourteen residues destabilize the blocked state. We have evidence 
from the ATPchase experiment that removal of those C-terminal residues removes the 
blocked state.  
 
 
Figure 32: Representation of the domains of each troponin subunit and interactions with 
other thin filament components55. Interaction underlined one represents a C-terminal 
TnT interaction with tropomyosin that holds tropomyosin in a blocked position. 
Interaction underlined two represents movement of the TnIreg that may be affected by 
the C-terminal of TnT interacting with either the inhibitory region (IR) of TnI or the 
hydrophobic region of TnC. 
 
Troponin is required for full activation of myosin ATPase activity73. We now have 
evidence that removal of the C-terminal fourteen amino acids of TnT increases 
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activation beyond that of wild type troponin. The H3 helix (or regulatory domain or 
switch region) of TnI is known to move into a hydrophobic pocket that opens on TnC at 
high calcium56 as indicated by the dotted red arrow in Figure 32 labelled 2. At high 
calcium, it is possible that the fourteen C-terminal amino acids of TnT function to inhibit 
movement of the H3 helix into the TnC hydrophobic region to limit activation by 
destabilizing the open state. There are several possible mechanisms for this to occur.  
At high calcium, the C-terminal of TnT may compete with or block the TnI H3 
helix from binding to the TnC hydrophobic region. If the last fourteen residues of the C-
terminal of TnT were absent as in the ∆14 TnT mutation, we would expect movement of 
the TnI H3 helix into the TnC hydrophobic region to be uncontested. This would allow 
the TnI H3 helix to more readily bind the hydrophobic region and remove TnI inhibition 
from tropomyosin. The TnI H3 helix would be more stable in the hydrophobic pocket 
without competition which would result in the more stabilized open state that we’ve 
observed from ATPase experiments. 
The close proximity of the C-terminal of TnT to the inhibitory domain of TnI also 
suggests an interaction which may limit stabilization of the open state. The C-terminal of 
TnT may interact with the TnI inhibitory domain to limit movement of the TnI regulatory 
region (TnIreg in Figure 32). By interacting with the TnI inhibitory domain, the C-terminal 
of TnT may increase the affinity of the TnIreg region for tropomyosin at high calcium 
which would limit the population of the actin open state. Removal of the last fourteen 
amino acids of the C-terminal of TnT (as in the ∆14 mutation) would remove the 
restraint placed on the inhibitory domain of TnI. Without restraint from the TnT C-
terminal, the TnIreg region could more readily move away from tropomyosin and stabilize 
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the open state. This same effect could be important in increasing the affinity of the TnIreg 
region for tropomyosin at low calcium to stabilize the blocked state This could explain 
the double effect of enhanced ATPase activity at both high and low calcium. 
Brunet et al. extensively characterized R145G TnI, R278C TnT, and a double 
mutant containing both R145G TnI and R278C TnT. In doing so they found that the 
R278C mutation was able to rescue some function lost by the R145G mutation alone. 
They concluded that the C-terminal of TnT may assist the inhibitory domain of TnI. This 
supports the idea of the C-terminal of troponin T functioning to inhibit movement of the 
TnIreg region about the TnI inhibitory domain. 
Characterization of troponin mutants within regions of the troponin complex 
known to be essential in maintaining normal cardiac function have proven to be useful 
markers for characterization of individual states of actin. Interpretation of the effect of 
mutants on the M state in Ca2+ requires knowing the level of activity when fully in the 
open state. The A8V TnC results show that ∆14 is approximately 70% in the open state 
whereas A8V/∆14 is essentially 100% in the open state. We were able to estimate the 
distribution for the mutants with that assumption. The A8V mutation also shows that 
stabilizing the open state can be done independently of inhibition on the blocked state.  
In combination with the ∆14 mutation, the A8V/∆14 double mutant appears to be 
a powerful promoter of the open state for which we’ve found to be indistinguishable from 
activation by the commonly incorporated NEM-S1. This double mutant provides a 
standard for characterizing the M state and for determining the fraction of occupancy of 
that state. This mutation also allows for further characterization of the open state without 
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modification to myosin S1. This could be very useful in studying mutations of myosin S1 
and how they affect binding to uninhibited actin. 
The blocked and closed states of actin have similar ATPase activities with S1. 
The R146G TnI mutant is very useful as it represents a highly enriched closed state. 
This is particularly true in Ca2+ where more than 90% of the actin filaments are in the C 
state. Stabilization of the closed state by the R146G TnI mutation can be incorporated 
as a useful standard for seeing how experiments are affected by a closed state inducing 
mutation. The ability to induce the closed state by R146G TnI will also allow further 
characterization of the closed state itself.  
Although the B and C states lack the ability to stimulate myosin ATPase, other 
properties of the C state are unclear. Myosin S1-ATP binds with similar affinity to the 
blocked, closed and open states83. However, rigor S1 and S1-ADP bind more tightly to 
the C and M states and the kinetics of binding are more rapid25. It is less clear if the C 
and M states are identical in their myosin binding properties. If the blocked state binds 
slowly and if the closed and open states bind equally quickly, we should see that the 
A8V/∆14 and R146G TnI mutant regulated actin have the same rate of S1 binding in 
Ca2+ as wild type troponin regulated actin. If so, then approximations of the Geeves 
model for predicting the blocked-closed state equilibrium are correct. We observed that 
that the rate of S1 binding in Ca2+ to A8V/∆14 regulated actin or R146G TnI regulated 
actin was similar to the observed rates of S1 binding to wild type troponin regulated 
actin.  
Identifying the mechanism by which calcium induces movement of tropomyosin 
via troponin is important to understanding how mutations in the troponin complex cause 
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cardiovascular disease. By characterizing the far C-terminal region of troponin T, as well 
as mutations in both TnI and TnC, we are one step closer to understanding how 
mutations in these regions disrupt function.  
In summary, this work has confirmed that the C-terminal region of TnT has two 
unique regulatory functions. We have shown that the two regulatory functions may 
involve slightly different regions of the C-terminus. Whereas stabilization of the blocked 
state requires the entire C-terminal region, three specific regions appear to be most 
critical for destabilizing the open state. There are now two new potential therapeutic 
targets in the C-terminal region of TnT. In addition, once the binding partners of these 
regions has been identified in EGTA and Ca2+ we will have identified two additional 
targets.  
In completing this work, it was useful to study two additional mutants. Troponin 
containing A8V TnC partially stabilized the open state and in combination with ∆14TnT 
the open state was totally stabilized. This is an important tool that can be useful to 
characterize the M state. 
Finally, the R146G TnI mutation stabilized the closed state and is the first 
troponin mutant shown to do so. Also, the ability to induce 91% of the actin filaments in 
the closed state will be a useful tool for further investigations of contractile regulation.  
This work represents the beginning of the description of a new regulatory feature 
of cardiac and skeletal muscle.
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 Appendix C: Protein Preparation 
 
Skeletal Actin Preparation 
Adapted from Ebashi, S.; Kodama, A. J Biochem 1965, 58 (1), 107–108. 
Day 1 
1.  Make 2 liters G-actin buffer 
a. 0.5 mM ATP, 2 mM Tris-pH 7.8, 0.1 mM CaCl2, B-mercaptoethanol 
2. Add 270 ml of actin solution /9 g powder. Gently stir every 10 minutes for 30 
minutes. Stir gently so as not to extract actinin or tropomyosin. 
3. Centrifuge 60 minutes near top speed of Sorvall SS-34 rotor (18,000 rpm) 
4. Tare empty beaker. Filter supernatant into beaker through glass wool or Whatman 
# 541 paper. Approximate volume by mass. 
5. Add solid potassium chloride to 3.3 M 
a. assume that potassium chloride increases the volume by 10 % 
6. Stir at room temp until the temperature reaches 15 C.  
7. Place on ice without stirring until temp reaches 5 C.  
8. Centrifuge in Sorvall SS-34 rotor at 18,000 rpm for 40 minutes. 
9. Dialyze supernanant against 32 volumes of 2 mM Tris, 1mM MgCl2 pH 7.6. The 
final concentration of KCl is now 0.1 M. Actin is now in “F” form. 
 
Day 2 
10. Add 4 M KCl to the actin to give a final concentration of 0.8 M.  
a. Volume of KCl to add is 0.219 x volume of actin.  
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11. Stir for 1 hour at 4C.  
12. Centrifuge for 1.5 hour at 45,000 rpm in a Ti 50.2 rotor.  
13. Remove pellets into homogenizer with less than 25 ml of G-buffer and 
homogenize  
14. Tare a beaker (150 ml) and add actin to estimate volume by its mass. 
15.  Add sequentially with stirring: 1.5 ml 100 mM MgCl2, 0.75 ml 4 M KCl, G-buffer to 
bring total volume to 77.25 ml 
16. Place on ice over night or proceed to Day 3\ 
 
Day 3 
17.  Add 18 ml of 4 M KCl and 4.75 ml G-buffer 
18. Stir for 1.5 hours at 4C. 
19. Centrifuge 1.5 hours at 45,000 rpm in Ti 50.2 rotor.  
20. Remove pellets into homogenizer with less than 25 ml of G-buffer and 
homogenize. 
21.  Dialyze against G-buffer with at least three changes of buffer. Change buffer 
every 12 hours.  
 
Day 5 
22. Homogenize G-actin.  
23. Centrifuge 1.5 hours at 30,000 RPM in a Ti 50.2 rotor. 
24. Weigh the actin to estimate the volume.  
25. While stirring vigorously add sequentially: 1 M MOPS pH 7 buffer to get 10 mM, 
25 mM MgCl2 to get  1 mM 
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26. Dialyze in F-actin solution at least 24 hours 
a. 4 mM MOPS, pH 7, 2 mM  MgCl2 , 0.5 mM ATP 
27. Add sodium azide to the actin to a final of 0.01%.  
28. Store actin at 4C 
 
Removal of residual ATP before use 
29. Centrifuge at 45,000 RPM for two hours in a Ti 50.2 rotor 
30. Pour off supernatant and set aside (check O.D. to ensure low actin concentration) 
31. Remove pellet into homogenizer with less than 10 ml F-actin solution and 
homogenize 
32. Measure Absorbance spectrum from 260 nm to 340 nm 
33. ATP-free actin should exhibit the following 
a. A280/A290=1.8 
b. A280/A260=1.5 
34. Concentration in mg/ml = (A280-A320)/1.15  
 
Storage 
Store in G-actin form at 5mg/l by adding surcrose to 10mg/ml or by freezing in liquid 
Nitrogen. Store at -70C.   
89 
 
Myosin Preparation 
Adapted from: Leonard A. Stein, Richard P. Schwarz Jr., P. Boon Chock, and Evan 
Eisenberg. Biochemistry 1979 18 (18), 3895-3909 DOI: 10.1021/bi00585a009 
 
Day 1 
1. Kill 5-6 lb rabbit by bleeding. 
2. Dissect back and leg muscles quickly and place on ice 
3. Grind and weigh. (Should have about 300 grams) 
4. Extract 12 minutes with 3 volumes of ice cold extracting solution. Stir in cold. 
a. 0.5 M KCl, 0.1 M K2HPO4, 10 mM PMSF, pH 6.5 
5. Centrifuge at 7,000 RPM, 4 degrees Celsius for 15 minutes in GSA rotor.  
6. Filter supernatant through four layers of cheesecloth and collect. Estimate 
volume. 
a. Pellet may be saved for acetone powder prep 
7. Carefully adjust to pH 6.6 
8. Dilute with 10 volumes ice cold water over the course of 2-3 minutes 
9. Check that pH is still below 6.8 and correct as needed 
10. Centrifuge at top speed in IEC rotor. Discard supernatant. 
11. Weight pellets to estimate volume 
12. Add 2 M KCl to 0.5 M to make solution 
a. Liters 2M KCl = 0.303 x volume pellet 
13. Pool pellets into one bottle. Rinse residual protein from bottles with 0.5 M KCl. 
Keep total volume under 550 mL 
14. Adjust pH to 6.75 using 0.1 M NaHCO3 
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15. Measure volume 
Day 2 
16. Dilute to 0.28 M KCl with ice cold water with stirring 
a. Volume Cold Water = volume solution x 0.786 
17. Centrifuge at top speed in Sorvall GSA rotor 
18. Discard precipitate 
19. Measure supernatant volume 
20. Dilute to 0.4 M KCl with ice cold water and stirring 
a. Volume Cold Water = volume solution x 6 
21. Allow to stand one hour in the cold 
22. Centrifuge at top speed in IEC rotor for 20 minutes 
23. Discard supernatant 
24. Combine and weigh pellets to estimate volume 
25. Bring to 0.5 M KCl with ice cold 2 M KCl and stir to dissolve 
a. volume 2 M KCl = volume pellets x 0.3 
26. Dialyze versus 1 liter of 0.5 M NaCl, 0.1 mM DTT 
Storage 
27. Add ice cold glycerol to 50% glycerol and store at -20 degrees Celsius 
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Myosin S1 Preparation 
Adapted from: Leonard A. Stein, Richard P. Schwarz Jr., P. Boon Chock, and Evan 
Eisenberg. Biochemistry 1979 18 (18), 3895-3909 DOI: 10.1021/bi00585a009 
 
Day 1 
1. Dialyze myosin 50% glycerol stock extensively against 30 mM NaCl, 2 mM 
MOPS pH 7, 1 mM DTT. 
Day 2 
2. Centrifuge in Sorvall SS-34 rotor at 18,000 RPM for 1 hour 
3. Discard supernatant 
4. Estimate pellet volume and dissolve myosin by adding solid KCl to 1 M 
5. Suspend the pellets in 0.5 M NaCl, 10 mM MOPS pH 7, 1 mM DTT and dialyze 
against same buffer 
Day 3 
6. Measure the concentration and dilute to 15 mg/ml if needed 
7. Dialyze overnight against 0.12 M NaCl, 10 mM NaPi pH 7.2, 1 mM EDTA, 1 mM 
DTT, 0.1 mM NaN3 
Day 4 
8. Measure myosin volume 
9. Prepare 100 mM PMSF by dissolving 34 mg in 1 mL isopropyl alcohol. Dissolve 
by warming and sonicating. 
10. Prepare chymotrypsin by dissolving 5 mg in 1 mL water. Store on ice. 
11. Warm myosin to 22-25 degrees Celsius 
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12. Add chymotrypsin solution using a 1/100 dilution with rapid stirring. Final 
concentration is 0.05 mg/ml 
13. Maintain myosin temperature between 22 and 25 degrees Celsius and stir ten 
minutes 
14. Add 100 mM PMSF using a 1/200 dilution with rapid stirring. Final concentration 
0.5 mM. 
15. Allow to set in ice 10 minutes 
16. Dialyze over night against 40 mM NaCl, 5 mM NaPi, 1 mM DTT, pH 6.5 at 4 
degrees Celsius 
Day 5 
17. Centrifuge at 40,000 RPM for one hour in a Ti 50.2 rotor 
18. Collect supernatant 
19. Precipitate the S1 by adding 100% ammonium sulfate to 60% saturation 
20. Centrifuge at 18,000 RPM in sorvall SS-34 rotor for 30 minutes 
21. Pour of supernatant 
a. Pellets can covered with 60% ammonium sulfate at this step and kept on 
ice for two months 
22. Dissolve pellet in 2 mM MOPS pH 7, 50 mM KCl, 1 mM DTT and dialyze versus 
same buffer 
Day 6 
23. Dialyze versus buffer of choice before use 
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Preparation of Ether powder from bovine cardiac muscle for the production of 
troponin and tropomyosin 
Adapted from: Potter (1982; volume 85 of methods in Enzymology) 
 
At 4 degrees C 
1) Mince trimmed beef cardiac muscle 
2) Add 5 volumes of wash solution and homogenize.  
a. 1% triton, 50 mM KCl, 5 mM Tris pH 8 
3) Homogenize 1 minute at high speed (5-7) 
4) Centrifuge at 10960 g for 15 min. Discard supernatant. 
5) Pellets are suspended in equal volume of wash solution in centrifuge bottle and 
rehomogenized 
6) Centrifuge at 10960xg for 15 min 
7) Repeat steps 5-7, 8-10 times (cardiac residue turns almost white) 
At room temp 
8) Pellets transferred to a 4 Liter plastic beaker 
9) Three volumes cold 95% ethanol added 
10) Break up pellets with gloved hand 
11) Tissue is collected over Buchner funnel on 4 liter filter flask. 26cm diameter, 
Whatman No. 1 filter paper. Discard filtrate 
12) Repeat steps 1-5, 3 more times 
13) Repeat steps 1-6 using diethyl ether in place of ethanol 
14) Leave to dry overnight on filter paper 
15) Weigh and store at 4 degrees C  
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Preparation of Bovine Cardiac Troponin from Ether Powder 
Adapted from: Potter (1982; volume 85 of methods in Enzymology) 
 
1. Bovine cardiac ether powder is extracted in a 20 vol/gram powder of 1M KCl, 20 
mM MOPS, pH7.0, 1 mM DTT, 0.01% NaN3, 25 mg/L Benzamidine, 10 mg/L  
Leupeptin, 5 mg/L Pepstatin A , 10 mg/L TLCK, 3 mg/l TPCK, 15 mM BME 
2. Stir overnight at 4C. 
3. Centrifuge 1 hour at 45,000 rpm in a Ti50.2 rotor. 
4. Carefully remove supernatant and adjust to pH 8.0 with 1N KOH. 
5. Measure volume  
6. Add 167g of  ammonium sulfate per liter of supernatant with constant stirring at 4 
degrees Celsius  
7. Allow to stir one hour 
8. Centrifuge in Sorvall SS-34 rotor for 30 min at 15,000rpm.  
9. Remove supernatant and measure volume 
10. Add 73g/Liter of ammonium sulfate to bring the ammonium sulfate from 30% to 
42.5%. 
11. After stirring 1 hour, centrifuge 30 min at 15,000 rpm in SS-34 rotor.  
12. Save supernatant for Tropomyosin  
a. Collect 65% ammonium sulfate fraction after adding 168 g ammonium 
sulfate per liter. Proceed to BvC Tropomyosin prep. 
13. Dialyze BvC Troponin against 20 mM MOPS pH 7, 50 mM NaCl, 1 mM DTT  
14. Equilibrate a Mono Q DEAE column with the same buffer 
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15.  Centrifuge 30 minutes at 40,000 rpm in a Ti 50.2 rotor to remove any precipitate. 
16. Load supernatant onto DEAE column and wash with two column of starting 
buffer.  
17. Run a ten column volume gradient to 1 M NaCl  
a. The cardiac troponin should elute in the middle of the gradient 
18. Check OD280-340 of fractions and run SDS-PAGE gel along with MW ladder to 
identify clean fractions 
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Preparation of Bovine Cardiac Tropomyosin from Ether Powder 
Adapted from: Potter (1982; volume 85 of methods in Enzymology) 
 
1. The 65% ammonium sulfate pellet from the BvC troponin protocol was brought 
up in minmal buffer and dialyzed extensively against the same buffer 
a. 1 M KCl, 2 mM MOPS, pH 7.2, 5 mM B-ME 
2. Equilibrate a hydroxylapatite column with 1 M KCl, 1 mM PO4, pH 7.2, 2 mM DTT 
3. The sample was spun at 30 minutes at 40,000 rpm in a Ti 50.2 rotor to clarify 
4. The sample was loaded onto the hydroxylapatite column 
5. The column was washed with two column volumes of equilibration buffer 
6. Elute protein with a five column volume gradient of phosphate to 250 mM 
a. Protein should elute near end of gradient 
7. Check OD280-340 and combine fractions with protein 
8. Carefully bring tropomyosin to pH 4.6 and allow to rest overnight on ice 
9. Centrifuge at 30,000 rpm for 40 minutes pour off supernatant 
10. Dissolve pellet in 4 mM MOPS, 40 mM KCl pH 7 or buffer of choice 
11. Run SDS-Page gel along with MW standard to verify purification 
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Recombinant Troponin C Preparation from 4 L TnI/TnC Culture 
Adapted from:  
Gafurov, B.; Chen, Y. D.; Chalovich, J. M. Biophys J 2004, 87 (3), 1825–1835. 
 
1) Prepare 2L 6 M Urea, 1 mM EDTA, 20 mM Tris/HCl, pH 8 (Soln. A) 
2) Prepare 1L Soln. A + 0.5 M NaCl 
3) Suspend pellet w/ about 40 mL Solution A + protease inhibitors 
a. Sigma 8465 cocktail. 43 mg dissolved in ~0.4 mL DMSO, ~1.6 mL water. 
b. Leupeptin to ~10 µM (~2.5 mg dissolved in ~1.0 mL water) 
c. Pepstatin to ~1 µM (~1.0 mg dissolved in ~1.0 mL DMSO) 
4) Sonicate 20 seconds x four times on ice 
5) Centrifuge at 19K for 1 hour at 4 C. TnI/TnC is in supernatant. 
6) Equilibrate DE52 (DEAE) column with cold solution A 
7) Add DTT and protease inhibitors 
a. DTT to 1 mM 
b. PMSF to 1mM. (17.4mg in 10 mL isopropanol for 10 mM stock. Store at -
20 C) 
c. Leupeptin and Pepstatin (as in step 3) 
8) Apply to DEAE column. 
a. TnI shouldn’t stick to column. Purify by TnC affinity column. 
b. TnC should stick 
c. Elute TnC with gradient to 0.5 M NaCl 
9) Gel to confirm TnC. Combine fractions containing TnC. 
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10) Dialyze versus Phenyl sepharose start buffer. 2-3 changes.  
a. 1 M NaCl, 1 mM CaCl2, 50 mM Tris pH 8 
11) Equilibrate Phenyl sepharose column w/ start buffer 
12) Apply sample to column.  
13) Wash column w/ 250 mL start buffer. 
14) Wash column w/ 250 mL 1 M NaCl, 0.2 mM CaCl2, 50 mM Tris pH 8 
15) Elute TnC w/ 250 mL 5 mM EDTA, 20 mM Tris/HCl pH 8 
a. Wash further w/ buffer if no peak appears 
16) Run SDS-Page gel 
17) Dialyze versus experiment buffer or buffer containing at least 200 mM NaCl/KCl 
and 2 mM DTT 
18) Add DTT to 2 mM before freezing in liquid N2 or dry ice/ethanol. Store at -80 C. 
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Troponin I Purification using TnC Affinity Column 
Adapted from: Pharmacia Fine Chemicals Affinity Chromatography principles and 
methods. Sweden, Ljungforetagen AB, Orebro, August 1983 
 
1. Dialyze clean Troponin C against coupling buffer 
a. 0.2 M NaHCO3, 0.5 M NaCl, pH 8.3 
2. Suspend freeze dried CnBr activated sepharose in ice cold 1 mM HCl 
a. 1 gram powder gives 3.5 mL gel volume. Use 5 mg protein per mL of gel 
3. Wash 15 minutes on sintered glass filter (porosity G3) using 200 mL 1 mM HCl 
per gram of dry powder in small aliquots. Final aliquot is sucked off until cracks 
appear in gel. 
4. Transfer gel immediately to troponin C solution using a gel to troponin C solution 
ratio of 1:2 
5. Allow to mix 2 hours end over end at room temperature 
6. Make 2 M ethanolamine pH solution that is equal in volume to the gel-TnC 
mixture 
7. Add 2 M ethanolamine solution to gel-TnC mixture to give ethanolamine 
concentration of 1 M 
8. Allow to mix end over end for 2 hours at room temperature 
9. Allow mixture to settle 
10. Suck off superanatant 
11. Wash alternately with coupling buffer and wash buffer three times each 
a. Wash buffer: 0.1 M acetate, 0.5 M NaCl, pH 4 
100 
 
12. Suspend in wash buffer and pour into clean, dry column 
13. Wash column with ten column volumes of wash buffer 
14. Dialyze impure Troponin I from DEAE column from TnC/TnI culture prep against 
6 M Urea, 0.1 mM CaCl2, 20 mM Tris/HCl, pH 8.0, 1 mM DTT 
15. Equilibrate TnC affinity column with same buffer 
16. Load TnI onto column and wash with two to four column volumes start buffer 
17. Collecting fractions equivalent to about half the loaded volume 
18. Elute with 6 M urea, 0.5 M NaCl, 1 mM EDTA, 20 mM Tris/HCl, pH 8.0, 1 mM 
DTT 
19. Run SDS-page gel to verify purification 
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Recombinant TnT Preparation from 4L Culture  
Adapted from:  
Gafurov, B.; Chen, Y. D.; Chalovich, J. M. Biophys J 2004, 87 (3), 1825–1835. 
 
1) Prepare 4L 6 M Urea, 1 mM EDTA, 20 mM Tris/HCl, pH 8 (Soln. A) 
2) Prepare 1L Soln. A + 0.5 M NaCl 
3) Suspend pellet w/ about 40 mL Solution A + protease inhibitors 
a. About 1.0 mg pepstatin dissolved in 0.1 mL DMSO 
b. About 2.5 mg leupeptin dissolved in ~1.0 mL water 
c. About 0.25 mg TPCK dissolved in 0.1 mL water 
d. About 0.25 mg TLCK dissolved in 0.1 mL water 
e. 43 mg sigma cocktail P8340 dissolved in 0.4 mL DMSO 
4) Sonicate 20 seconds x 6-8 times on ice 
5) Centrifuge at 19K for 1 hour at 4 degrees Celsius in Sorvall SS-34 rotor.  
6) Measure supernatant volume 
7) Add 176 g/L ammonium sulfate to 30% saturation. Let stir one hour at 4 degrees 
Celsius 
8) Centrifuge at 19,000 rpm for 30 minutes at 4 degrees Celsius in Sorvall SS-34 
rotor 
9) Measure supernatant volume 
10) Add 94 g/L ammonium sulfate to 45% saturation. Let stir one hour at 4 degrees 
Celsius 
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11) Centrifuge at 19,000 rpm for 30 minutes at 4 degrees Celsius in Sorvall SS-34 
rotor 
12) Measure supernatant volume 
13) Add 110 g/L ammonium sulfate to 45% saturation. Let stir one hour at 4 degrees 
Celsius 
14) Centrifuge at 19,000 rpm for 30 minutes at 4 degrees Celsius in Sorvall SS-34 
rotor 
15) Save precipitate and suspend in about 30 mL solution A + protease inhibitors 
16) Dialyze versus 2 L of solution A 
17) Centrifuge at 19,000 rpm for 15 minutes to clarify 
18) Equilibrate Mono Q DEAE column with solution A 
19) Apply sample and wash with one column volume solution A 
20) Run 10 column volume gradient of solution A from 0.1 to 0.6 M NaCl 
21) Run 1 column volume gradient from 0.6 M NaCl to 1 M NaCl 
22) Continue washing with about 5 column volumes 1 M NaCl 
23) Check OD280-340 
24) Run SDS-PAGE gel to verify purification 
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Troponin Reconstitution 
Adapted from: Kobayashi, T. & Solaro, R. J. (2006) Increased Ca2+ Affinity of Cardiac 
Thin Filaments Reconstituted with Cardiomyopathy-related Mutant Cardiac Troponin I, 
Journal of Biological Chemistry. 281, 13471-13477. 
 
1. Dialyze each troponin subunit against 1 M NaCl, 5 mM MgCl2, 5 mM DTT, 20 mM 
MOPS pH 7 
2. Measure concentrations of each troponin subunit using Lowry assay 
3. Mix TnT, TnI and TnC at a 1:1:1.05 molar ratio and dialyze against two changes 
of the same buffer with the addition of 6 M urea 
4. Dialyze against two changes of the same buffer without urea. 
5. Dialyze against same buffer as step 4 but with 0.3 M NaCl. 
6. Dialyze against same buffer as step 4 but with 0.1 M NaCl. 
7. Dialyze against 0.1 M NaCl, 5mM MgCl2, and 20 mM Tris/HCl, pH 8.0 
8. Centrifuge at 30,000 rpm for 40 minutes in a Ti 50.2 rotor  
9. Equilibrate a Mono Q DEAE column with 0.1 M NaCl, 5mM MgCl2, and 20 mM 
Tris/HCl, pH 8.0. 
10. Load troponin onto column and wash with two column volumes start buffer 
11. Elute with a linear gradient of 0.1–0.6 M NaCl in the same solution 
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Modification of tropomyosin with the fluorescent probe acrylodan 
Adapted from: Ishii and Lehrer, Biochemistry 29 1160-1166, 1990 
 
1. Dialyze tropomyosin against reducing buffer:  
a. 100 mM KCl, 10 mM Pi buffer pH 6.5, 5 mM EDTA, 1 mM DTT.   
2. Add sufficient Pi buffer pH 6.0 to bring the final buffer concentration to 50 mM.  
3. Add DTT to 10 mM and incubate for at least 30 min. at 37oC. 
4. Dialyze the tropomyosin extensively against 3 mM MOPS, pH 7.5, 0.1 mM 
EDTA.   
5. Add guanidine HCl to the tropomyosin to make it 4 M  
6. Add a 5-fold excess of 6-Acryloyl-2-Dimethylaminonaphthalene and allow to 
react overnight at room temperature in the dark and with a nitrogen atmosphere. 
Remaining steps are done in dark. 
7. Stop the reaction by adding an excess of DTT.  
8. Centrifuge 30,000 rpm in a Ti 50 rotor for 20 min. Save the supernatant.  
9. Dialyze against at least 20-volumes 4M guanidine HCl, 3 mM MOPS, 0.1 mM 
EDTA. The dialysis should be changed 4 times at 8-12 hour intervals 
10. Dialyze extensively against 40 mM NaCl, 5 mM Mops, pH 7 or buffer of choice   
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Modification of actin with the fluorescent probe pyrene 
Adapted from: Brenner & Korn (1983) JBC 258, 5013-5020 
 
1. Weigh out between 1.4 and 2 mg of pyrenyl iodoacetamide and add 
dimethylformamide to bring to 14 mg/ml.  
2. Prepare Dilution Buffer:  
a. 100 mM Tris-HCl, pH 8.0, 1M KCl, 20 mM MgCl2, 1 mM CaCl2, 0.1% NaN3.  
3. Prepare Actin Buffer: 1 liter of actin buffer containing 4 mM imidazole, 2 mM 
MgCl2, 1 mM DTT. 
4. To 20 mg of F-actin in actin buffer (4mM imidazole, 2 mM MgCl2) add 1 ml of 
Dilution Buffer and water to 10 ml. 
a.  The water should be added to the dilution buffer prior to addition to actin. 
5. Stir in the dark until the actin is homogeneous. 
6. Add 0.1 ml of pyrenyl-iodoacetamide and incubate 12 hours at 20oC in the dark. 
7. Add a small flake of DTT to stop the reaction. 
8. Centrifuge the actin in a 50 Ti rotor for 20 min at 30,000 rpm.  
9. Save the supernatant containing the pyrenyl actin. 
a. The pellet is unreacted pyrenyliodoacetamide. 
10. Centrifuge the supernatant in the 50Ti rotor at 45,000 rpm for 1h.  
11. Discard the supernatant.  
12. Add 5 ml of actin buffer to the pellet and allow to stand on ice in the dark for 1hr 
13. Homogenize the pellet and dialyze overnight in 500 ml of actin buffer with out DTT.  
14. Determine the concentration of actin as described in the Actin prep. 
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15. Determine the extent of labeling at 344 nm using an extinction coefficient of 2.2E4 
M-1cm-1.  
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Protein Detection and Concentration Measure Using Spectrophotometer 
 
1. Set spectrophotometer to measure absorbance at 280 nm and to subtract out 
absorbance at 340 nm 
2. Add protein buffer to each 1 cm path length cell and correct baseline  
3. Add protein to cell and collect A280-340 
Concentration (mg/mL) = ABS/Extinction Coefficient 
Concentration (uM) = mg/mL x E6 / MW 
Protein Molecular Weight, MW (grams/mol) Extinction Coefficient  
Myosin S-1 120,000 0.75 
Actin 42,000 1.15* 
Myosin 480,000 0.56 
BSA 64,000 0.66  
HC Troponin T 35,923 0.504 
HC Troponin I 24,000 0.397 
HC Troponin 
C 18,400 0.214 
Troponin 71,000 0.37 
*See actin prep 
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Lowry Assay 
Adapted from: O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall, J. Biol. 
Chem. 193, 265 (1951). 
 
1. Bring 1-20 µg protein to 0.2 mL with water in a 1.5 mL Eppendorf tube 
a. Make 3 solutions of different concentrations for each protein to be 
measured as well as 3 solutions of a standard protein (such as BSA) of 
known concentration. Also make one blank solution with no protein. 
2. Add 0.2 mL reagent A to each solution 
a. 1 part CTC, 1 part 0.8 M NaOH, 2 parts 5% SDS 
i. CTC: 0.1% w/v CuSO4*5 H2O, 0.2% w/v sodium/potassium tartrate, 
10% w/v Na2CO3 
3. Vortex and let stand 10 minutes 
4. Add 0.1 mL reagent B 
a. 1 part 2 N Folin reagent, 5 parts water 
5. Vortex and let stand 30 minutes 
6. Turn on spectrophotometer and set wavelength to 680nm 
7. Zero baseline using blank 
8. Measure absorbance at 680 nm for each solution 
9. Plot each protein absorbance versus the volume of protein added 
10. Calculate the slope of each  
11. Determine protein concentration using: 
[Protein] =
slope unknown
slope BSA
∗ [BSA]  
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Pouring polyacrylamide gel 
 
1) Assemble gel cartridge 
2) For two 12% gels add the following to a 15 mL conical tube 
a. 3.2 mL sterile H2O 
b. 4 mL Acrylamide/Bis-acrylamide (30%/0.8% w/v) 
c. 2.6 mL 1.5 M Tris pH 8.8 
d. 0.1 mL 10% SDS 
e. 0.1 mL 10% ammonium persulfate (added immediately before pouring) 
f. 0.010 mL Temed (added immediately before pouring) 
3) Quickly close and invert conical. Use disposable pipet to transfer solution to the 
cartridge. Leave about 2 cm of space from the top. 
4) Add solid butanol above solution 
5) Allow to sit at least thirty minutes but no longer than 2 hours at room temperature 
6) For two stacking gels add the following to a 15 mL conical tube 
a. 3 mL sterile H2O 
b. 0.67 mL Acrylamide/Bis-acrylamide (30%/0.8% w/v) 
c. 1.25 mL 0.5 M Tris pH 6.8 
d. 0.05 mL 10% SDS 
e. 0.05 mL 10% ammonium persulfate (added immediately before pouring) 
f. 0.005 mL Temed (added immediately before pouring) 
7) Quickly close and invert conical. Use disposable pipet to transfer solution to the 
cartridge. Fill nearly to top. 
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8) Place loading spacer into cartridge immediately 
9) Allow to sit at least thirty minutes 
10) Remove spacer 
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Preparing Samples and Running SDS-PAGE gel 
 
1. Add 30 µL of each protein to 1.5 mL Eppendorf tubes 
a. If protein is close to or greater than 10 mg/mL, use less than 30 µL and 
bring up to 30 µL with buffer or water 
2. Add 7 µL of 5X loading buffer to each 
a. 10% SDS, 10 mM DTT, 20% w/v glycerol, 0.2 M Tris-HCl pH 6.8 
3. Boil each tube 5 minutes 
4. Transfer poured and polymerized polyacrylamide gel to running apparatus 
5. Fill apparatus with Laemmli buffer 
a. 0.2 M glycine, 0.01 M Tris Base, 0.035 mM SDS 
6. Load between 5 and 20 uL protein solutions 
7. Connect apparatus to voltage source 
8. Run at 75 volts until sample is past the stacking gel. Can then turn voltage up to 
150 volts if desired. 
9. Turn off voltage source once front nears bottom of gel 
10. Remove gel cartridge and carefully transfer gel to small container 
11. If using coomassie stain, cover the gel with the coomassie solution. 
a. 10% acetic acid, 30% methanol, 0.01% coomassie 
12. Optional: Cover loosely with lid and microwave 30 seconds 
13. Allow to mix overnight on rocker (or ten minutes if microwaved) 
14. Pour off coomassie stain solution 
15. Wash gel extensively with destain. 30% methanol, 0.01% coomassie 
 Appendix D: Supplementary Experiments 
 
Figure 33: Comparing Myosin S1 binding at high (A and B) and low (C and D) Ca2+ to 
actin regulated by unlabeled (A and C) or acrylodan labelled (B and D) tropomyosin. 1 
µM skeletal Actin 0.43 µM BvC tropomyosin mixed rapidly with 1 µM skeletal myosin 
S1. Conditions: 20 mM MOPS, 90 mM KCl, 4 mM MgCl2, 2 mM EGTA, 1 mM DTT. 
Filter: 435/451/460nm. Temp: 10° C. Excitation: 391 nm. Slit Width: 0.5 mm. This figure 
demonstrates that ….. 
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Figure 34: Comparing rate of Myosin A1S1 to Myosin S1 binding to actin at low Ca2+. A) 
Myosin S1 binding at high Ca2+. B) Myosin S1 binding at low Ca2+. C) Myosin A1 S1 
binding at low Ca2+.2 µM skeletal actin stabilized with phalloidin, 0.86 µM BvC 
tropomyosin and 0.86 µM hc troponin mixed rapidly with 1 µM skeletal myosin S1. 
Conditions: 20 mM MOPS, 90 mM KCl, 4 mM MgCl2, 2 mM EGTA, 1 mM DTT. Filter: 
435/451/460nm. Temp: 10° C. Excitation: 391 nm. Slit Width: 0.5 mm. 
This figures demonstrates that Myosin S1 (a mixture of A1 and A2 isoforms) and Myosin 
A1S1 (Isolated Myosin A1S1) both bind to actin more slowly at low calcium and at a 
similar rate. 
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Figure 35: Time course of transition from the open to the closed and blocked state 
measured by acrylodan tropomyosin fluorescence for actin regulated by BvC 
tropomyosin in the absence of troponin.2 µM skeletal actin, 2 µM skeletal S1 and 0.86 
µM bovine cardiac acrylodan tropomyosin were rapidly mixed with 2 mM ATP. 
Conditions: 90 mM KCl, 20 mM Mops, 4 mM MgCl2, 2 mM EGTA, 1 mM DTT. Filter: 
435/451/460. 10°C. 391nm excitation. This figure shows that in the absence of troponin, 
there is no increase in fluorescence corresponding to a transition from the closed to 
blocked state. Transition to the blocked state requires troponin. 
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Figure 36: Time course of transition from the open to the closed and blocked state 
measured by acrylodan tropomyosin fluorescence for actin regulated by tropomyosin 
and either wild type (A), ∆14 TnT (B) or A8V/∆14 double mutant at high calcium. 2 µM 
skeletal actin, 2 µM skeletal S1, 0.86 µM bovine cardiac acrylodan tropomyosin, and 
0.86 µM human cardiac troponin were rapidly mixed with 2 mM ATP. Conditions: 90 mM 
KCl, 20 mM Mops, 4 mM MgCl2, 0.5 mM CaCl2, 1 mM DTT. Filter: 435/451/460. 10°C. 
391nm excitation.This shows that at high calcium, no transition to the blocked state 
occurs. 
 
  
